

Curriculum Vitae di Claudio Luchini

(redatto ai sensi degli artt. 46 e 47 del D.P.R. 445/2000)

Il Sottoscritto Claudio Luchini, consapevole della responsabilità penale ai sensi degli artt. 75 e 76 del D.P.R. 445/2000 per le ipotesi di falsità in atti e dichiarazioni mendaci ivi indicate:

DICHIARA

che le informazioni riportate in questo documento sono veritiere.

INFORMAZIONI PERSONALI

- **E-mail:** claudio.luchini@univr.it
- **Nazionalità / Cittadinanza:** Italiana
- **Ordine professionale:** Ordine dei Medici Chirurghi di Trento (n.03927)

PRESENTAZIONE

come da sito univr (<https://www.ddsp.univr.it/?ent=persona&id=14576>)

Laurea in Medicina e Chirurgia, Specializzazione in Anatomia Patologica, Dottorato di Ricerca in Infiammazione, Immunità e Cancro.

Research Scholar presso l'Indiana University School of Medicine ad Indianapolis (2014) e research fellow presso il Sol Goldman Pancreatic Cancer Research Center della Johns Hopkins University a Baltimora (2014-2015).

Autore di oltre 350 pubblicazioni e contributi scientifici, prettamente rivolti allo studio della patologia chirurgica e molecolare delle neoplasie del pancreas e delle vie biliari.

Coautore delle linee guida OMS / WHO sull'adenocarcinoma duttale del pancreas, neoplasie intraduttali del pancreas, tumori ereditari del pancreas, e delle sindromi genetiche tumorali Peutz-Jeghers and PALB2-relate.

Coautore delle raccomandazioni della Società Europea di Oncologia Medica sull'Instabilità dei Microsatelliti nel cancro.

Chair dell'Education Committee della Pancreato-Biliary Pathology Society (*PBPS-USCAP*).

Associate Editor di Virchows Archiv (rivista ufficiale della Società Europea di Patologia), di BMC Gastroenterology e Endocrine Oncology, e membro dell'Editorial Board di Human Pathology, World Journal of Gastrointestinal Oncology e Pathology: Research and Practice.

STUDI, FORMAZIONE MEDICA

<i>Luglio 2003:</i>	Diploma presso il Liceo Scientifico “L. Da Vinci” di Trento
<i>Luglio 2009:</i>	Laurea in Medicina e Chirurgia, Università degli Studi di Verona.
<i>Febbraio 2010:</i>	Abilitazione professionale all’esercizio della Professione Medica presso l’Università degli Studi di Verona.
<i>Maggio 2015:</i>	Specializzazione in Anatomia Patologica, Università di Verona, con voto 70/70 e lode.
<i>Aprile 2018:</i>	Dottore di Ricerca, Scuola di Dottorato in Scienze della Vita e della Salute, Corso: Infiammazione, Immunità e Cancro, Università di Verona (XXX ciclo)

CONOSCENZA LINGUE

Italiano (scritto e parlato) madrelingua; Inglese (scritto e parlato) ottimo; Tedesco (scritto e parlato) elementare

INQUADRAMENTO LAVORATIVO

- Professore Ordinario di Anatomia Patologica (L. 240/10) presso l’Università di Verona
- Gruppo scientifico disciplinare: 06/MEDS-04 Anatomia Patologica
- Settore scientifico disciplinare: MEDS-04/A Anatomia Patologica

ATTIVITA’ LAVORATIVA

2 Dicembre 2015 – 31 Ottobre 2017: Dirigente Medico a tempo indeterminato, UOM Anatomia ed Istologia Patologica e Citodiagnostica, APSS, Trento.

1 Novembre 2017 – 30 Settembre 2019: Ricercatore a tempo determinato di tipo A, Dipartimento di Diagnostica e Sanità Pubblica, Sezione di Anatomia Patologica, Università di Verona, e Dirigente Medico, UOC Anatomia e Istologia Patologica, Azienda Ospedaliera Universitaria Integrata, Verona.

1 Ottobre 2019 – 28 Febbraio 2026 : Professore Associato, Dipartimento di Diagnostica e Sanità Pubblica, Sezione di Anatomia Patologica, Università di Verona, e Dirigente Medico, UOC Anatomia e Istologia Patologica, Azienda Ospedaliera Universitaria Integrata, Verona.

1 Marzo 2026 – oggi : Professore Ordinario, Dipartimento di Diagnostica e Sanità Pubblica, Sezione di Anatomia Patologica, Università di Verona, e Dirigente Medico, UOC Anatomia e Istologia Patologica, Azienda Ospedaliera Universitaria Integrata, Verona..

ATTIVITA’ CLINICO-ASSISTENZIALE

Il Prof. Luchini svolge attività clinico-assistenziale come dirigente medico anatomo-patologo e si occupa di:

-Patologia gastro-enterica e bilio-pancreatica

-Patologia molecolare

ATTIVITA' DIDATTICA

Come docente nei corsi di laurea

- Dall'A.A. 2017/18: docente nel Corso di Laurea in Tecniche di Laboratorio Biomedico, insegnamento di Metodologie Diagnostiche di Anatomia Patologica, modulo di Patologia Molecolare (crediti annui del docente: 2 nell'A.A. 2017/18 e 2018/19, ed 1 dall'A.A. 2020/21 ad oggi)
- Dall'A.A. 2017/18: docente/tutor nel Corso di Laurea Magistrale in Medicina e Chirurgia, nelle esercitazioni nel corso di Anatomia Patologica Clinica (gruppo Prof. Luchini; crediti annui del docente: 1)
- Dall'A.A. 2018/2019 al 2021/22: docente responsabile del corso elettivo "Caratteristiche istopatologiche e molecolari dei tumori gastroenterici e bilio-pancreatici", Corso di Laurea in Medicina e Chirurgia (crediti annui del docente: 1)
- Dall'A.A. 2024/2025: docente nel Corso di Laurea Magistrale in Medicina e Chirurgia, insegnamento di Anatomia Patologica generale (crediti annui del docente: 0,5)
- Dall'A.A. 2024/2025: docente nel Corso di Laurea Magistrale in Medicina e Chirurgia, insegnamento di Anatomia Patologica clinica (crediti annui del docente: 0,5)

Come docente nei corsi di dottorato

- Dall'A.A. 2019/20: docente nel Corso di Dottorato "Infiammazione, Immunità e Cancro" (crediti annui lezioni del docente: 1,25 nell'A.A. 2023/24, e 0,5 dall'A.A. 2024/25 ad oggi)

Come docente nelle scuole di specializzazione

- Dall'A.A. 2017/18: docente nella Scuola di Specializzazione in Anatomia Patologica (crediti annui del docente: 5,25 nell'A.A. 2017/18, 3 nell'A.A. 2018/19, e 10,5 dall'A.A. 2019/20 ad oggi)
- Dall'A.A. 2018/19: docente nella Scuola di Specializzazione in Malattie dell'Apparato Digerente (crediti annui del docente: 1,5 dall'A.A. 2018/19 all'A.A. 2022/23, e 2 dall'A.A. 2023/24 ad oggi)
- Dall'A.A. 2018/19: docente nella Scuola di Specializzazione in Geriatria (crediti annui del docente: 1 dall'A.A. 2018/19 ad oggi)
- Dall'A.A. 2018/19: docente nella Scuola di Specializzazione in Dermatologia e Venereologia (crediti annui del docente: 2 dall'A.A. 2018/19 ad oggi)
- Dall'A.A. 2019/20: docente nella Scuola di Specializzazione in Reumatologia (crediti annui del docente: 0,5 dall'A.A. 2019/20 ad oggi)
- Dall'A.A. 2023/24: docente nella Scuola di Specializzazione in Genetica Medica (crediti annui del docente: 1 dall'A.A. 2023/24 ad oggi)

Come componente di commissioni di esame in corsi di laurea

- Componente della commissione di esame di Metodologie Diagnostiche di Anatomia Patologica, Corso di Laurea in Tecniche di Laboratorio Biomedico dall'A.A. 2017/18 ad oggi
- Componente della commissione di esame di Anatomia Patologica Generale, Corso di Laurea in Medicina e Chirurgia dall'A.A. 2017/18 ad oggi
- Componente della commissione di esame di Anatomia Patologica Clinica, Corso di Laurea in Medicina e Chirurgia dall'A.A. 2024/25 ad oggi

Come componente di commissioni di esame finale di laurea, di diploma o di assegni di ricerca

- Componente della commissione dell'Esame Finale di Specializzazione in Anatomia Patologica in 2 occasioni.
- Componente della commissione dell'Esame Finale di Laurea in Medicina e Chirurgia in 7 occasioni.
- Presidente commissione giudicatrice per 2 assegni di ricerca di dipartimento e componente di commissione giudicatrice per altri 3 assegni di ricerca.

Come correlatore di tesi di laurea o di specializzazione

- Correlatore tesi di laurea in Medicina e Chirurgia dal titolo "CD200 nelle neoplasie pancreatiche non duttali: pattern di espressione ed implicazioni clinico-diagnostiche".
- Correlatore tesi di laurea in Medicina e Chirurgia dal titolo "Carico mutazionale ed instabilità microsatellitare negli IPMN del pancreas: implicazioni per l'immunoterapia".

- Correlatore tesi di laurea in Medicina e Chirurgia dal titolo “Gli adenocarcinomi del colon con instabilità dei microsatelliti e metastasi linfonodali: valutazione istopatologica del tumore primitivo e delle metastasi associate”.
- Correlatore tesi di laurea in Medicina e Chirurgia dal titolo “Caratterizzazione clinico-patologica e molecolare delle neoplasie neuroendocrine del pancreas ad alta cinetica proliferativa”.
- Correlatore tesi di laurea in Medicina e Chirurgia dal titolo “Le neoplasie cistiche mucinose del pancreas come precursore dell’adenocarcinoma infiltrante: dall’istologia al profilo molecolare”.
- Correlatore tesi di specializzazione in Anatomia Patologica dal titolo “Il ruolo della cancerizzazione di campo nell’adenocarcinoma duttale del pancreas: studio istologico e molecolare di una serie di adenocarcinomi primitivi con ricorrenza locale”.
- Correlatore tesi di specializzazione in Anatomia Patologica dal titolo “Trasformazione cistica acinare del pancreas: coorte originale e revisione sistematica della letteratura”.

Come relatore di tesi di laurea o di specializzazione

- Relatore tesi di laurea in Medicina e Chirurgia dal titolo “Caratterizzazione isto-molecolare delle neoplasie intraduttali tubulo-papillari del pancreas”.
- Relatore tesi di laurea in Medicina e Chirurgia dal titolo “Studio istologico e molecolare delle cisti acinari pancreatiche: trasformazioni benigne o vere neoplasie?”.
- Relatore tesi di specializzazione in Anatomia Patologica dal titolo “Le neoplasie intraduttali tubulo-papillari del pancreas”.
- Relatore tesi di laurea in Tecniche di Laboratorio Biomedico dal titolo “Linfomi a grandi cellule B primitivi del sistema nervoso centrale: studio immunoistochimico e molecolare di una casistica”.
- Relatore tesi di laurea in Tecniche di Laboratorio Biomedico dal titolo “Impiego della metodica di next generation sequencing per la valutazione della percentuale di frequenza allelica variante in pazienti affetti da melanoma con mutazione *BRAF* V600E”.

Partecipazione a reti e partenariati europei e internazionali di università, attività di internazionalizzazione di ateneo, mobilità e scambio

- Responsabile del progetto “Comprehensive integrative genetic and epigenetic analysis of MEN1 mutated tissues and neuroendocrine tumors”, finanziato nell’ambito del programma di internazionalizzazione di Ateneo (Università di Verona) Cooper-Int, Azione 3, Categoria A2, con invito del Prof. Lodewijk Brokens (UMC Utrecht, Olanda) per 1 mese presso il Dipartimento di Diagnostica e Sanità Pubblica, Sezione di Anatomia Patologica.

ESPERIENZE PROFESSIONALI E DI RICERCA ALL’ESTERO

Scholarship / Fellowship

8 Agosto – 31 Ottobre 2014:

Research Scholar presso Dipartimento di Patologia e Medicina di Laboratorio, Indiana University School of Medicine, Indianapolis, IN, USA (responsabile Prof. Liang Cheng).

11 Novembre 2014 – 30 Aprile 2015:

Research Fellow presso Dipartimento di Patologia, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University, Baltimore, MD, USA (responsabile Prof.ssa Laura D. Wood).

Visiting

5 febbraio – 6 febbraio 2024:

Visiting presso Universitätsklinikum di Düsseldorf, Düsseldorf, Germania, per condivisione di casi paradigmatici di patologia pancreato-biliare e discussione di progetti di ricerca con la direttrice dell'Istituto di Patologia, Prof.ssa Irene Esposito.

6 maggio – 7 maggio 2024:

Visiting presso la Division di Anatomic Pathology, Mayo Clinic, Rochester, MN, USA, per condivisione di casi paradigmatici di patologia pancreato-biliare e discussione di progetti di ricerca con il responsabile della patologia gastrointestinale, Prof. Rondell P. Graham.

PARTECIPAZIONE AD ATTIVITA' DI TERZA MISSIONE DELL'UNIVERSITA'

- Partecipazione al progetto “Lezioni Aperte 2019”, individuato come attività nell'ambito della “Terza Missione” dell'Università, con possibilità di frequentazione di studenti del Liceo ad una lezione frontale (Corso di Metodologie diagnostiche di anatomia patologica, Modulo di Patologia Molecolare, Lezione del 7 marzo 2018, 3 studenti partecipanti).
- Collaborazione con il sito PathologyOutlines.com, uno dei principali siti web nel contesto della patologia chirurgica e molecolare, con il ruolo di autore e revisore di diversi capitoli e di editor della sezione ampolla e piccolo intestino.
- Partecipazione come relatore alla giornata mondiale per la cura del tumore del pancreas in cui i membri dell'Istituto del pancreas incontrano la cittadinanza della città di Verona (data 21 novembre 2024, titolo della relazione: “Ma è sempre maligno? È sempre un adenocarcinoma?”)

AFFILIAZIONI E RUOLI IN SOCIETA' SCIENTIFICHE

- Coordinatore nazionale della sezione *journal club* per il pancreas del Gruppo Italiano Patologi dell'Apparato Digerente (GIPAD-SIAPEC) dal 2014 al 2019 (per la versione online consultare: <http://www.gipad.it/journal-club/>).
- Membro della Società Europea di Anatomia Patologica - European Society of Pathology ESP, dal 2020 ad oggi
- Membro della Società Europea di Oncologia Medica – European Society of Medical Oncology ESMO, dal 2023 ad oggi.
- Membro dell'International Study Group of Pancreatic Pathologists (ISGPP) dal 2019 ad oggi.
- Membro della Pancreatobiliary Pathology Society (PBPS) e della United States and Canadian Academy of Pathology (USCAP) dal 2019 ad oggi.
- Membro del Grossing Working Group della PBPS-USCAP dal 2021 ad oggi.
- Chair dell'Education Committee della PBPS-USCAP dal 2024 ad oggi, con ruolo organizzativo delle sessioni pancreato-biliari in corsi, seminari e congressi, ivi compreso il congresso annuale USCAP.
- Membro dell'Executive Committee della PBPS-USCAP dal 2024 ad oggi.

PARTECIPAZIONE A COLLEGIO DOCENTI / DOTTORATO DI RICERCA

Partecipazione al collegio italiano dei professori di anatomia patologica

- Ottobre 2019-Ottobre 2024 oggi: membro del Consiglio Direttivo del Collegio Italiano dei Professori di Anatomia Patologica (Consigliere – Rappresentante PA).
- Ottobre 2024- oggi: membro della Commissione Didattica nel Collegio Italiano dei Professori di Anatomia Patologica.

Partecipazione a collegio docenti / dottorato di ricerca / consigli dipartimentali e di scuole di specializzazione

- Aprile 2020- oggi: membro del Collegio Docenti del Dottorato di Ricerca in Infiammazione, Immunità e Cancro, Dipartimento di Medicina, Università di Verona
- Ottobre 2017- oggi: membro del Consiglio del Dipartimento di Diagnostica e Sanità Pubblica, Università di Verona, del Collegio didattico del Corso di Laurea in Medicina e Chirurgia, del Collegio didattico del Corso di Laurea in Tecniche di Laboratorio Biomedico, Università di Verona
- Ottobre 2017- oggi: componente del Consiglio della Scuola di Specializzazione in Anatomia Patologica, Università di Verona
- Dall'A.A. 2018/19- oggi: componente del Consiglio della Scuola di Specializzazione in Malattie dell'Apparato Digerente, Università di Verona
- Dall'A.A. 2018/19- oggi: componente del Consiglio della Scuola di Specializzazione in Geriatria, Università di Verona
- Dall'A.A. 2018/19- oggi: componente del Consiglio della Scuola di Specializzazione in Dermatologia e Venereologia, Università di Verona
- Dall'A.A. 2019/20- oggi: componente del Consiglio della Scuola di Specializzazione in Reumatologia, Università di Verona
- Dall'A.A. 2023/24- oggi: componente del Consiglio della Scuola di Specializzazione in Genetica Medica, Università di Verona

PROGETTI DI RICERCA FINANZIATI

Come Principal Investigator (PI) del progetto

PI (principal investigator / coordinatore) del progetto “A novel integrative taxonomy for accelerating precision medicine in periampullary cancers” (CUP B53D23008010006), nell'ambito dei Progetti di ricerca di Rilevante Interesse Nazionale (PRIN) 2022, periodo 2023-2025.

Vincitore Progetto Cassini 2017, bando di ricerca per sostenere attività di studio e ricerca con ricercatori delle università francesi, finanziato dall'Ambasciata di Francia in Italia. Il Prof. Luchini risulta coordinatore del progetto, che vede la collaborazione tra Università di Verona e Università “Descartes” di Parigi.

Come Responsabile di unità locale del progetto

Responsabile di unità locale del progetto “Therapy tailoring in gastric cancer: identification of biomarkers of response to anti-EGFR treatments” (CUP B53D23030690001), nell'ambito dei Progetti di ricerca di Rilevante Interesse Nazionale (PRIN) 2022, periodo 2023-2025: responsabile di unità locale dal 2 novembre 2024 ad oggi ancora in corso.

Responsabile di unità locale del progetto “Pancreatic tumor genome: clinical application of the results” (CUP J37G22000230001) dal 2024 alla fine del progetto, durata 2022-2024, finanziato da FIMP – Fondazione Italiana per la ricerca sulle malattie del pancreas - Onlus / Ministero della Salute.

Finanziamenti ottenuti per assegni di ricerca

Co-responsabile del progetto di ricerca dal titolo “Caratterizzazione delle alterazioni morfologiche e molecolari di neoplasie pancreatiche con instabilità dei microsatelliti” con finanziamento di assegno di ricerca, co-finanziato dal Dipartimento di Diagnostica e Sanità Pubblica e da fondi FUR 2019.

Responsabile del progetto di ricerca dal titolo “Caratterizzazione clinica e molecolare dei tumori con differenziazione neuroendocrina ed epatoide” con finanziamento di assegno di ricerca, co-finanziato dal Dipartimento di Diagnostica e Sanità Pubblica e da fondi FUR 2018.

Attività come collaboratore del PI di ulteriori progetti

Collaboratore del PI nel progetto finanziato dal Ministero della Salute – PNRR 2023-2027 / Piano Nazionale Complementare Ecosistema Innovativo della Salute - Codice univoco investimento: PNC-E.3, “Hub diagnostica avanzata (HLS-DA) – INNOVA” (CUP: B33C22001850001).

PARTECIPAZIONE A STESURA DI LINEE GUIDA / RACCOMANDAZIONI SCIENTIFICHE

Partecipazione alla stesura della “Proposta di PDTA per pazienti affetti da tumori del pancreas – Rete Oncologica Veneta”, versione 2017 e versione 2025.

Partecipazione alla stesura delle raccomandazioni per l’analisi dei microsatelliti, quali marcatori di risposta per l’immunoterapia contro i tumori, della Società Europea di Oncologia Medica (ESMO). Tali raccomandazioni sono state raccolte nel lavoro scientifico dal titolo “ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach”, con autori Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard J-Y, André F, Scarpa A, pubblicato sulla rivista “Annals of Oncology” (2019, 30:1232-1243).

Partecipazione al consensus-meeting internazionale di esperti di patologia pancreatiche per la stesura di raccomandazioni per l’approccio al campionamento e alla refertazione di resezioni pancreatiche per adenocarcinoma duttale in contesto di terapia neoadiuvante. Da tale consensus meeting è nato il lavoro scientifico “Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy” pubblicato su Modern Pathology nel 2021, con il Prof. Luchini tra i coautori.

Partecipazione alla stesura delle linee guida / raccomandazioni per campionamento e refertazione istopatologica delle pancreatiti croniche. Da tale consensus meeting è nato il lavoro scientifico “Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club” pubblicato su Pancreatology (2020, 10:586-593), con il Prof. Luchini tra i coautori.

Partecipazione alla stesura delle “Raccomandazioni per l’implementazione dell’analisi mutazionale BRCA nei pazienti con carcinoma del pancreas avanzato (localmente avanzato / metastatico)” del gruppo di lavoro inter-societario AIOM-SIAPEC/IAP-SIBIOC-SICO-SIGE-SIGU. Le raccomandazioni sono state pubblicate con il Prof. Luchini tra i coautori: Russo A, et al. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO Open. 2022 Jun;7(3):100459.

Partecipazione alla stesura delle raccomandazioni PBPS / USCAP per la gestione anatomo-patologica dei casi di adenocarcinoma duttale del pancreas sottoposti a chemioterapia neoadiuvante, dal campionamento macroscopico alla clinica. Le raccomandazioni sono state pubblicate con il Prof. Luchini tra i coautori: Wang

H, et al. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society. Am J Surg Pathol. 2022 Jun 1;46(6):754-764.

ULTERIORE ATTIVITA' SCIENTIFICA

Attività di Editor per Riviste Scientifiche:

Associate Editor delle seguenti riviste scientifiche:

- Cancer Cell International, dal 2018 al 2021
- BMC Cancer, dal 2020 al 2022
- BMC Gastroenterology, dal 2019 ad oggi
- Endocrine Oncology, dal 2024 ad oggi
- Virchows Archiv, dal 2026 ad oggi

Review Editor delle seguenti riviste scientifiche:

- Frontiers in Oncology, dal 2020 al 2023

Guest Editor delle seguenti riviste scientifiche:

- PLoS One (per 3 differenti pubblicazioni)
- International Journal of Molecular Sciences (per 2 special issues)
- Archives of Pathology and Laboratory Medicine (per gli *special issues* della Pancreatobiliary Pathology Society PBPS/USCAP)

Attività di Editor e Autore per Siti Web scientifici:

- Editor per la sezione “piccolo intestino e ampolla” per il sito PathologyOutlines.com ed autore di 8 capitoli online per lo stesso sito.

Membro dell'Editorial Board di Riviste Scientifiche:

- Virchows Archiv
- Pathologica
- BMC Gastroenterology
- World Journal of Gastrointestinal Oncology
- Pathology: Research and Practice
- Human Pathology

Attività di Revisore per Riviste Scientifiche (peer-review):

Il Prof. Luchini ha svolto attività di revisore scientifico (peer-review) per un totale di n. 270 articoli su 76 differenti riviste scientifiche.

Attività di Revisore per progetti di ricerca

Il Prof. Luchini è stato revisore scientifico per conto della "Czech Science Foundation", agenzia di supporto alla ricerca in Repubblica Ceca, per la valutazione di validità e merito scientifici e congruità a finanziamento di un progetto di ricerca sul cancro del pancreas.

Il Prof. Luchini è stato revisore scientifico per conto di “The Latvian Council of Science (LCS)”, agenzia per il supporto alla ricerca in Lettonia, per la valutazione di validità e merito scientifici e congruità a finanziamento di due differenti progetti di ricerca sul cancro nella call “*Postdoctoral research 2025*”.

Attività di Revisore per tesi di dottorato

Il Prof. Luchini è stato revisore per 3 tesi di dottorato dell'Università degli Studi di Padova a partire dall'A.A. 2017/2018

Attività di Revisore per abstract inviati a convegni e congressi

Il Prof. Luchini ha svolto attività di revisore scientifico per abstract ai seguenti convegni e congressi: 34th European Congress of Pathology 2022, 35th European Congress of Pathology 2023, 36th European Congress

of Pathology 2024, USCAP 114th Annual Meeting 2025, 57th Annual Meeting of the European Pancreatic Club 2025, 37th European Congress of Pathology 2025.

PUBBLICAZIONI SCIENTIFICHE SU RIVISTA

	Google Scholar	Scopus
<i>h</i>-index	59	58
Citazioni	18354	16476

NUMERO TOTALE ARTICOLI SCIENTIFICI: 333 (Scopus)

NUMERO MEDIO CITAZIONI PER ARTICOLO: 49.47 (Scopus)

ELENCO DELLE PUBBLICAZIONI SCIENTIFICHE SU RIVISTA

Articoli come primo autore

1. **Luchini C**, Franzina C, Caldart F, De Pretis N, Crestani M, Donadelli M, Mattiolo P, Fiore A, Danzi F, De Robertis R, Bevere M, Baldan R, Tommasi L, Vianini N, Bernardi P, Galiè M, Pea A, Ciccocioppo R, D'Onofrio M, Salvia R, Verbeke C, Sbarbati A, Scarpa A, Veronese N, Frulloni L. Fatty pancreas disease: an integrated study on frozen tissues shows distinct compartments of inter/intra-lobular, intra-acinar, and intra-islet fat deposition. *Lab Invest* 2025 [In Press].
2. **Luchini C**; PathologyOutlines.com Review Committee; PathologyOutlines.com Contributors; Pernick N. Benign Tumors and Tumor-Like Conditions of Ampulla and Small Intestine: The PathologyOutlines.com Review. *Int J Surg Pathol*. 2025 May;33(3):528-539.
3. **Luchini C**. Diagnostic Pearls and Pitfalls in the Evaluation of Biopsies of the Pancreas. *Arch Pathol Lab Med*. 2025 Mar 1;149(3):e54-e62.
4. **Luchini C**, Scarpa A. Neoplastic Progression in Neuroendocrine Neoplasms of the Pancreas. *Arch Pathol Lab Med*. 2024 Sep 1;148(9):975-979.
5. **Luchini C**, Mattiolo P, Basturk O, Mafficini A, Ozcan K, Lawlor RT, Hong SM, Brosens LA, Marchegiani G, Pea A, Manfrin E, Sciacca G, Zampieri F, Polati R, De Robertis R, Milella M, D'Onofrio M, Malleo G, Salvia R, Adsay V, Scarpa A. Acinar Cystic Transformation of the Pancreas: Histomorphology and Molecular Analysis to Unravel its Heterogeneous Nature. *Am J Surg Pathol*. 2023 Mar 1;47(3):379-386.
6. **Luchini C**, Scarpa A. Microsatellite instability in pancreatic and ampullary carcinomas: histology, molecular pathology, and clinical implications. *Hum Pathol*. 2023 Feb;132:176-182.
7. **Luchini C**, Pantanowitz L, Adsay V, Asa SL, Antonini P, Girolami I, Veronese N, Nottegar A, Cingarlini S, Landoni L, Brosens LA, Verschuur AV, Mattiolo P, Pea A, Mafficini A, Milella M, Niazi MK, Gurcan MN, Eccher A, Cree IA, Scarpa A. Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring. *Mod Pathol*. 2022 Jun;35(6):712-720.
8. **Luchini C**, Pea A, Scarpa A. Artificial intelligence in oncology: current applications and future perspectives. *Br J Cancer*. 2022 Jan;126(1):4-9.
9. **Luchini C**, Mafficini A, Chatterjee D, Piredda ML, Sciammarella C, Navale P, Malleo G, Mattiolo P, Marchegiani G, Pea A, Salvia R, Brosens LA, Paolino G, Mastrosimini MG, Silvestris N, Milella M, Cheng L, Adsay VN, Lawlor RT, Scarpa A. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. *Virchows Arch*. 2022 Jun;480(6):1261-1268.

10. **Luchini C**, Lawlor RT, Bersani S, Vicentini C, Paolino G, Mattiolo P, Pea A, Cingarlini S, Milella M, Scarpa A. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? *Curr Oncol Rep*. 2021 Jul 16;23(9):106.
11. **Luchini C**, Pelosi G, Scarpa A, Mattiolo P, Marchiori D, Maragliano R, Sessa F, Uccella S. Neuroendocrine neoplasms of the biliary tree, liver and pancreas: a pathological approach. *Pathologica*. 2021 Feb;113(1):28-38.
12. **Luchini C**, Fassan M, Doglioni C, Capelli P, Ingravallo G, Renzulli G, Pecori S, Paolino G, Florena AM, Scarpa A, Zamboni G. Inflammatory and tumor-like lesions of the pancreas. *Pathologica* 2020;112:197-209.
13. **Luchini C**, Grillo F, Fassan M, Vanoli A, Capelli P, Paolino G, Ingravallo G, Renzulli G, Doglioni C, D'Amuri A, Mattiolo P, Pecori S, Parente P, Florena AM, Zamboni G, Scarpa A. Malignant epithelial/exocrine tumors of the pancreas. *Pathologica* 2020;112:210-226.
14. **Luchini C**, Paolino G, Mattiolo P, Piredda ML, Cavaliere A, Gaule M, Melisi D, Salvia R, Malleo G, Shin JI, Cargnini S, Terrazzino S, Lawlor RT, Milella M, Scarpa A. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. *J Exp Clin Cancer Res*. 2020;39:227.
15. **Luchini C**, Brosens LAA, Wood LD, Chatterjee D, Shin JI, Sciammarella C, Fiadone G, Malleo G, Salvia R, Kryklyva V, Piredda ML, Cheng L, Lawlor RT, Adsay V, Scarpa A. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. *Gut*. 2021 Jan;70(1):148-156.
16. **Luchini C**, Lawlor RT, Milella M, Scarpa A. Molecular Tumor Boards in Clinical Practice. *Trends Cancer*. 2020;6:738-744.
17. **Luchini C**, Veronese N, Nottegar A, Cappelletti V, Daidone MG, Smith L, Parris C, Brosens LAA, Caruso MG, Cheng L, Wolfgang CL, Wood LD, Milella M, Salvia R, Scarpa A. Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. *Cancers (Basel)*. 2019 Aug 10;11:1152.
18. **Luchini C**, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard J-Y, André F, Scarpa A. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach", *Ann Oncol* 30(8):1232-1243.
19. **Luchini C**, Pea A, Yu J, He J, Salvia R, Riva G, Weiss MJ, Bassi C, Cameron JL, Hruban RH, Goggins M, Wolfgang CL, Scarpa A, Wood LD, Lawlor RT. Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. *Mod Pathol*. 2019;32:659-665.
20. Smith L, **Luchini C** (co-primo autore), Demurtas J, Soysal P, Stubbs B, Hamer M, Nottegar A, Lawlor RT, Lopez-Sanchez GF, Firth J, Koyanagi A, Roberts J, Willeit P, Waldhoer T, Loosemore M, Abbs AD, Johnstone J, Yang L, Veronese N. Telomere length and health outcomes: an umbrella review of systematic reviews and meta-analyses of observational studies. *Ageing Res Rev*. 2019 Feb 15;51:1-10
21. **Luchini C**, Veronese N, Nottegar A, Riva G, Pilati C, Mafficini A, Stubbs B, Simbolo M, Mombello A, Corbo V, Cheng L, Yachida S, Wood LD, Lawlor RT, Salvia R, Scarpa A. Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis. *Pancreas*. 2019 Jan;48(1):70-76.
22. **Luchini C**, Cros J, Pea A, Pilati C, Veronese N, Rusev B, Capelli P, Mafficini A, Nottegar A, Brosens LAA, Noë M, Offerhaus GJA, Chianchiano P, Riva G, Piccoli P, Parolini C, Malleo G, Lawlor RT, Corbo V, Sperandio N, Barbareschi M, Fassan M, Cheng L, Wood LD, Scarpa A. PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. *Hum Pathol*. 2018 Nov;81:157-165
23. **Luchini C**, Nottegar A, Vaona A, Stubbs B, Demurtas J, Maggi S, Veronese N. Female-specific association among I, J and K mitochondrial genetic haplogroups and cancer: A longitudinal cohort study. *Cancer Genet*. 2018 Aug;224-225:29-36.
24. **Luchini C**, Veronese N, Nottegar A, Cheng M, Kaneko T, Pilati C, Tabbò F, Stubbs B, Pea A, Bagante F, Demurtas J, Fassan M, Infante M, Cheng L, Scarpa A. Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. *Virchows Arch*. 2018 Jun;472(6):939-947.
25. Nottegar A, Tabbo F, **Luchini C** (co-primo autore), Brunelli M, Bria E, Veronese N, Santo A, Cingarlini S, Gilioli E, Oglioni C, Eccher A, Montagna L, Pedron S, Doglioni C, Cangini MG,

- Inghirami G, Chilosi M. Pulmonary adenocarcinoma with enteric differentiation: Immunohistochemistry and molecular morphology. *Appl Immunohistochem Mol Morphol*. 2018 26(6):383-387.
26. **Luchini C**, Pea A, Lionheart G, Mafficini A, Nottegar A, Veronese N, Chianchiano P, Brosens LA, Noe M, Offerhaus GJ, Yonescu R, Ning Y, Malleo G, Riva G, Piccoli P, Cataldo I, Capelli P, Zamboni G, Scarpa A, Wood LD. Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma. *J Pathol* 2017; 243(2):148-154.
 27. **Luchini C**, Nottegar A. The Roles of Chromatin Remodeling Genes in Pancreatic-Biliary Malignancies. *Crit Rev Oncog*. 2017;22(5-6):471-479.
 28. **Luchini C**, Fleischmann A, Boormans J, Fassan M, Nottegar A, Lucato P, Stubbs B, Solmi M, Porcaro A, Veronese N, Brunelli M, Scarpa A, Cheng L. Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis. *Sci Rep* 2017; 7:2374.
 29. Cappellesso R, **Luchini C** (co-primo autore), Veronese N, Lo Mele M, Rosa-Rizzotto E, Guido E, De Lazzari F, Pilati P, Farinati F, Realdon S, Solmi M, Fassan M, Rugge M. Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis. *Hum Pathol*. 2017; 65:62-70.
 30. **Luchini C**, Robertson SA, Hong SM, Felsenstein M, Anders RA, Pea A, Nottegar A, Veronese N, He J, Weiss MJ, Capelli P, Scarpa A, Argani P, Kapur P, Wood LD. PBRM1 loss is a late event during the development of cholangiocarcinoma. *Histopathology* 2017; 71(3):375-382.
 31. **Luchini C**, Wood LD, Cheng L, Nottegar A, Stubbs B, Solmi M, Capelli P, Pea A, Sergi G, Manzato E, Fassan M, Bagante F, Bollschweiler E, Giacomuzzi S, Kaneko T, de Manzoni G, Barbareschi M, Scarpa A, Veronese N. Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: A systematic review with meta-analysis. *J Clin Pathol*. 2016 69:956-961.
 32. **Luchini C**, Veronese N, Yachida S, Cheng L, Nottegar A, Stubbs B, Solmi M, Capelli P, Pea A, Barbareschi M, Fassan M, Wood LD, Scarpa A. Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis. *Genes Chromosomes Cancer*. 2016;55:741-749.
 33. **Luchini C**, Veronese N, Pea A, Sergi G, Manzato E, Nottegar A, Solmi M, Capelli P, Scarpa A. Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater: A systematic review and meta-analysis of its prognostic significance. *Eur J Gastroenterol Hepatol*. 2016;28:205-209.
 34. **Luchini C**, Parcesepe P, Nottegar A, Parolini C, Mafficini A, Remo A, Chilosi M, Manfrin E. CD71 in gestational pathology: A versatile immunohistochemical marker with new possible applications. *Appl Immunohistochem Mol Morphol*. 2016;24:215-220.
 35. **Luchini C**, Nottegar A, Solmi M, Sergi G, Manzato E, Capelli P, Scarpa A, Veronese N. Prognostic implications of extranodal extension in node-positive squamous cell carcinoma of the vulva: A systematic review and meta-analysis. *Surg Oncol*. 2016;25:60-65.
 36. **Luchini C**, Chilosi M, Manfrin E. The importance of immunohistochemistry in the differential diagnosis of molar disease. *Pathologica*. 2016;108:151-153 (IF: 0, Corresponding Author)
 37. **Luchini C**, Nottegar A, Solmi M, Veronese N. Meta-analysis in pathology. *J Pathol & Microbiol* 2016. 1(1):1002.
 38. **Luchini C**, Capelli P, Scarpa A. Pancreatic ductal adenocarcinoma and its variants. *Surg Pathol Clin*. 2016;9:547-560.
 39. **Luchini C**, Veronese N, Solmi M, Cho H, Kim JH, Chou A, Gill AJ, Faraj SF, Chau A, Netto GJ, Nakayama K, Kyo S, Lee SY, Kim DW, Yousef GM, Scorilas A, Nelson GS, Kobel M, Kalloger SE, Schaeffer DF, Yan HB, Liu F, Yokoyama Y, Zhang X, Pang D, Lichner Z, Sergi G, Manzato E, Capelli P, Wood LD, Scarpa A, Correll CU. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: A systematic review and meta-analysis. *Oncotarget*. 2015;6:39088-39097.
 40. **Luchini C**, Parcesepe P, Mafficini A, Nottegar A, Parolini C, Veronese N, Remo A, Manfrin E. Specific expression patterns of epithelial to mesenchymal transition factors in gestational molar disease. *Placenta*. 2015;36:1318-1324.
 41. **Luchini C**, Capelli P, Fassan M, Simbolo M, Mafficini A, Pedica F, Ruzzenente A, Guglielmi A, Corbo V, Scarpa A. Next-generation histopathologic diagnosis: A lesson from a hepatic carcinosarcoma. *J Clin Oncol*. 2014;32:e63-66.

Lettere all'editore come primo autore

42. **Luchini C**, Wang H. Familial Versus Nonfamilial Origin of Acinar Cystic Transformation of the Pancreas: An Important Question to Address. *Pancreas*. 2024 Mar 1;53(3):e298-e299.
43. **Luchini C**, Nottesgar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, Veronese N. Extranodal extension is an important prognostic parameter for both colonic and rectal cancer. *Ann Oncol*. 2016;27:955-956.
44. **Luchini C**, Veronese N. The importance of extranodal extension in metastatic head and neck squamous cell carcinoma, in the light of the new AJCC cancer staging system. *Oral Oncol*. 2017;66:e1-e2.
45. **Luchini C**, Nottesgar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, Veronese N. Significance of the prognostic stratification of extranodal extension in colorectal cancer. *Ann Oncol*. 2016;27:1647.

Editoriali come primo autore

46. **Luchini C**, Grant RC, Scarpa A, Gallinger S. Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different? *Gut*. 2021 Oct;70(10):1809-1811.
47. **Luchini C**. Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells: a challenging cancer with new horizons? *Virchows Arch*. 2021 Mar;478(3):595-596.
48. **Luchini C**, Cheng L. Predicting the biological behavior of non-muscle-invasive bladder cancer: from histology to molecular taxonomy. *Transl Androl Urol*. 2017 Oct;6(5):987-990.
49. **Luchini C**, Veronese N. Extranodal extension of nodal metastasis is the main prognostic moderator in squamous cell carcinoma of the esophagus after neoadjuvant chemoradiotherapy. *J Thorac Dis*. 2017 Oct;9(10):3609-3612.

Articoli come ultimo autore e/o corresponding author

50. Carrara S, Bevere M, Delle Cave D, Gentiluomo M, Esposito I, **Luchini C**. Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives. *Dig Liver Dis*. 2026 [Epub ahead of print]
51. Franzina C, Bevere M, Bersani S, Mattiolo P, Ceccon C, Piccoli P, Malleo G, Lawlor RT, Salvia R, Milella M, Fassan M, Scarpa A, **Luchini C**. High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation for targeted therapy. *Hum Pathol*. 2026 Feb;168:106014.
52. Mattiolo P, Zen Y, Zhang X, Scarpa A, **Luchini C** (corresponding author), Graham RP. Biliary adenofibroma and cholangiocarcinoma: neighbors or relatives? A systematic and critical review. *Hum Pathol*. 2025 Jul 12:105872.
53. Di Lecce C, Eccher S, Simbolo M, Cocomazzi A, Piredda ML, Caliò A, Cima L, Munari E, Veronese N, Avancini A, Zanconati F, Milella M, Scarpa A, Pilotto S, Belluomini L, **Luchini C**. ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR. *Lung Cancer*. 2025 Jul;205:108594.
54. Pea A, Bevere M, Gkoutakos A, Pasini D, Fiorini D, Mafficini A, Golovco S, Simbolo M, Pedron S, Sciammarella C, Mattiolo P, Mombello A, Villanova M, Franzina C, Masetto F, Ciulla C, Sperandio N, Fujikura K, Ahadi MS, Samra JS, Johns AL, Verheij J, Stommel MWJ, van Santvoort H, Schubert Santana L, Malleo G, Milella M, Brosens LAA, Wood LD, Chang DK, De Robertis R, D'Onofrio M, Gill AJ, Salvia R, Corbo V, Lawlor RT, Scarpa A, **Luchini C**. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characterization. *J Pathol*. 2025 Aug;266(4-5):421-434.
55. Lionetto G, Mattiolo P, Ciulla C, Savegnago G, Casciani F, De Pastena M, Paiella S, Pea A, Esposito A, Crovetto A, Donadelli M, Franzina C, Fassan M, Scarpa A, Salvia R, Malleo G, **Luchini C**. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical value of Intratumor Heterogeneity. *Ann Surg*. 2024 Oct 15. doi: 10.1097/SLA.0000000000006565. Epub ahead of print.

56. Mattiolo P, Bevere M, Mafficini A, Verschuur AVD, Calicchia M, Hackeng WM, Simbolo M, Paiella S, Dreijerink KMA, Landoni L, Pedron S, Cingarlini S, Salvia R, Milella M, Lawlor RT, Valk GD, Vriens MR, Scarpa A, Brosens LA, **Luchini C**. Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres). *Endocr Pathol*. 2024 Dec;35(4):354-361.
57. Mattiolo P, De Bellis M, Mafficini A, Fassan M, Bevere M, Ciulla C, Bersani S, Lawlor RT, Milella M, Scarpa A, **Luchini C** (co-last author e corresponding author), Ruzzenente A. Long-Term Survivor of Intrahepatic Cholangiocarcinoma for over 18 Years: Case Study with Longitudinal Histomolecular and Tumor Immune Microenvironment Characterization and Systematic Review of the Literature. *J Gastrointest Cancer*. 2024 Dec;55(4):1634-1646.
58. Paolino G, Basturk O, Esposito I, Hong SM, Brosens LA, Tarcan Z, Wood LD, Gkountakos A, Omori Y, Mattiolo P, Ciulla C, Marchegiani G, Pea A, Bevere M, De Robertis R, D'Onofrio M, Salvia R, Cheng L, Furukawa T, Scarpa A, Adsay V, **Luchini C**. Comprehensive Characterization of Intraductal Oncocytic Papillary Neoplasm of the Pancreas: A Systematic and Critical Review. *Mod Pathol*. 2024 Sep;37(9):100554.
59. Masetto F, Mafficini A, Saka B, Armutlu A, Chatterjee D, Jang KT, Zen Y, Navale P, Fassan M, Bacchi CE, Mattiolo P, Simbolo M, Ruzzenente A, Lawlor RT, Reid M, Basturk O, Adsay V, Scarpa A, **Luchini C**. Tubulocystic Carcinoma of Bile Ducts: A Distinct Type of Cholangiocarcinoma Associated With Adenofibroma-type Lesions. *Am J Surg Pathol*. 2024 Sep 1;48(9):1082-1092.
60. Ciulla C, **Luchini C**. Genomic determinants of biological aggressiveness and poor prognosis of pancreatic cancers: *KRAS* and beyond. *Expert Rev Mol Diagn*. 2024 May;24(5):355-362.
61. Gkountakos A, Singhi AD, Westphalen CB, Scarpa A, **Luchini C**. Fusion genes in pancreatic tumors. *Trends Cancer*. 2024 May;10(5):430-443.
62. Mattiolo P, Wang H, Basturk O, Brosens LAA, Hong SM, Adsay V, Scarpa A, **Luchini C**. Comprehensive characterisation of acinar cystic transformation of the pancreas: a systematic review. *J Clin Pathol*. 2023 Nov;76(11):740-746.
63. Mastrosimini MG, Mafficini A, Tondulli L, Milella M, Piccoli P, Mattiolo P, Fassan M, Hong SM, Scarpa A, **Luchini C**. Recurrent gastric amphicrine tumor with neuroendocrine and pancreatic acinar cell differentiation and somatic MEN1 inactivation arisen during immunotherapy. *Virchows Arch*. 2023 Sep;483(3):415-419.
64. Omori Y, Furukawa T, Scarpa A, **Luchini C**. Co-occurring IPMN and pancreatic cancer: the same or different? An overview from histology to molecular pathology. *J Clin Pathol*. 2023 Nov;76(11):734-739.
65. Simbolo M, Silvestris N, Malleo G, Mafficini A, Maggino L, Cocomazzi A, Veghini L, Mombello A, Pezzini F, Sereni E, Martelli FM, Gkountakos A, Ciaparrone C, Piredda ML, Ingravallo G, Paolino G, Nappo F, Rapposelli IG, Frassinetti L, Saragoni L, Lonardi S, Pea A, Paiella S, Fassan M, Brunetti O, Cingarlini S, Salvia R, Milella M, Corbo V, Lawlor RT, Scarpa A, **Luchini C**. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. *Mod Pathol*. 2023 Sep;36(9):100251.
66. Pea A, Paolino G, Martelli F, Bariani E, Piccoli P, Sereni E, Salvia R, Lawlor RT, Cheng L, Chang D, Scarpa A, **Luchini C**. Characterization and digital spatial deconvolution of the immune microenvironment of intraductal oncocytic papillary neoplasms (IOPN) of the pancreas. *Virchows Arch*. 2023 Aug;483(2):157-165.
67. Gkountakos A, Martelli FM, Silvestris N, Bevere M, De Bellis M, Alaimo L, Sapuppo E, Masetto F, Mombello A, Simbolo M, Bariani E, Milella M, Fassan M, Scarpa A, **Luchini C**. Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment. *Cancers (Basel)*. 2023 Feb 24;15(5):1454.
68. Mafficini A, Simbolo M, Shibata T, Hong SM, Pea A, Brosens LA, Cheng L, Antonello D, Sciammarella C, Cantù C, Mattiolo P, Taormina SV, Malleo G, Marchegiani G, Sereni E, Corbo V, Paolino G, Ciaparrone C, Hiraoka N, Pallaoro D, Jansen C, Milella M, Salvia R, Lawlor RT, Adsay V, Scarpa A, **Luchini C**. Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma. *Mod Pathol*. 2022 Dec;35(12):1929-1943.
69. Tsvetkova V, **Luchini C**. Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms of the Pancreas. *Surg Pathol Clin*. 2022 Sep;15(3):555-563.

70. Gkoutakos A, Mafficini A, Lou E, Malleo G, Salvia R, Calicchia M, Silvestris N, Racila E, Amin K, Veronese N, Brunetti O, Antonini P, Ingravallo G, Mattiolo P, Saponaro C, Nappo F, Simbolo M, Bariani E, Lonardi S, Fassan M, Milella M, Lawlor RT, Scarpa A, **Luchini C**. Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas. *Hum Pathol*. 2022 Oct;128:124-133.
71. Mattiolo P, Scarpa A, **Luchini C**. Hepatoid tumors of the gastrointestinal/pancreatobiliary district: morphology, immunohistochemistry, and molecular profiles. *Hum Pathol*. 2023 Feb;132:169-175.
72. Paolino G, Esposito I, Hong SM, Basturk O, Mattiolo P, Kaneko T, Veronese N, Scarpa A, Adsay V, **Luchini C**. Intraductal tubulopapillary neoplasm (ITPN) of the pancreas: a distinct entity among pancreatic tumors. *Histopathology*. 2022 Sep;81(3):297-309.
73. Mattiolo P, Mafficini A, Lawlor RT, Marchegiani G, Malleo G, Pea A, Salvia R, Piccoli P, Sciammarella C, Santonicco N, Parisi A, Silvestris N, Milella M, Adsay V, Scarpa A, **Luchini C**. "Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms. *Virchows Arch*. 2022 Jul;481(1):41-47.
74. Gkoutakos A, Simbolo M, Bariani E, Scarpa A, **Luchini C**. Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology. *Int J Mol Sci*. 2022 Jan 24;23(3):1283.
75. Mafficini A, Brosens LAA, Piredda ML, Conti C, Mattiolo P, Turri G, Mastrosimini MG, Cingarlini S, Crinò SF, Fassan M, Piccoli P, Simbolo M, Nottegar A, Lawlor RT, Guglielmi A, Scarpa A, Pedrazzani C, **Luchini C**. Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants. *Fam Cancer*. 2022 Oct;21(4):441-451.
76. Milella M, **Luchini C** (corresponding author), Lawlor RT, Johns AL, Casolino R, Yoshino T, Biankin AV; ICGC-ARGO. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. *Lancet Oncol*. 2022 Jan;23(1):25-26.
77. Sciammarella C, Bencivenga M, Mafficini A, Piredda ML, Tsvetkova V, Paolino G, Mastrosimini MG, Hetoja S, de Manzoni G, Mattiolo P, Borga C, Fassan M, Scarpa A, **Luchini C** (co-last e corresponding author), Lawlor RT. Molecular Analysis of an Intestinal Neuroendocrine/Non-neuroendocrine Neoplasm (MiNEN) Reveals MLH1 Methylation-driven Microsatellite Instability and a Monoclonal Origin: Diagnostic and Clinical Implications. *Appl Immunohistochem Mol Morphol*. 2022 Feb 1;30(2):145-152.
78. Simbolo M, Bersani S, Vicentini C, Taormina SV, Ciaparrone C, Bagante F, Rusev B, Centonze G, Montresor M, Brunelli M, Pedron S, Mafficini A, Paolino G, Mattiolo P, Conci S, Milione M, Guglielmi A, Ruzzenente A, Scarpa A, **Luchini C**. Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles. *Expert Opin Ther Targets*. 2021 Dec;25(12):1095-1105.
79. Lawlor RT, Mafficini A, Sciammarella C, Cantù C, Rusev BC, Piredda ML, Antonello D, Grimaldi S, Bonizzato G, Sperandio N, Marchegiani G, Malleo G, Pea A, Salvia R, Mombello A, Mazzoleni G, Nottegar A, Hanspeter E, Riva G, Tomezzoli A, Bencivenga M, de Manzoni G, Pedron S, Paolino G, Mattiolo P, Brosens LA, Silvestris N, Fassan M, Cooke SL, Beer PA, Milella M, Adsay VN, Cheng L, Scarpa A, Luchini C. Genomic characterization of hepatoid tumors: context matters. *Hum Pathol*. 2021 Dec;118:30-41.
80. Lawlor RT, Mattiolo P, Mafficini A, Hong SM, Piredda ML, Taormina SV, Malleo G, Marchegiani G, Pea A, Salvia R, Kryklyva V, Shin JI, Brosens LA, Milella M, Scarpa A, **Luchini C**. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. *Cancers (Basel)*. 2021 Jun 22;13(13):3119..
81. Piredda ML, Ammendola S, Sciammarella C, Turri G, Bagante F, Fassan M, Mafficini A, Mombello A, Cataldi S, Paolino G, Mattiolo P, Florena AM, Genna M, Fior F, Cheng L, Lawlor RT, Scarpa A, Pedrazzani C, **Luchini C**. Colorectal cancer with microsatellite instability: Right-sided location and signet ring cell histology are associated with nodal metastases, and extranodal extension influences disease-free survival. *Pathol Res Pract*. 2021 Aug;224:153519.
82. Mafficini A, Lawlor RT, Ghimenton C, Antonello D, Cantù C, Paolino G, Nottegar A, Piredda ML, Salvia R, Milella M, Dei Tos AP, Fassan M, Scarpa A, **Luchini C**. Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different BRCA2 Germline Mutations: New Horizons from Tumor Molecular Profiling. *Genes (Basel)*. 2021 Mar 26;12(4):481.

83. Mattiolo P, Fiadone G, Paolino G, Chatterjee D, Bernasconi R, Piccoli P, Parolini C, El Aidi M, Sperandio N, Malleo G, Salvia R, Brosens LA, Wood LD, Scarpa A, Lawlor RT, **Luchini C**. Epithelial-mesenchymal transition in undifferentiated carcinoma of the pancreas with and without osteoclast-like giant cells. *Virchows Arch*. 2021 Feb;478(2):319-326.
84. Fassan M, Scarpa A, Remo A, De Maglio G, Troncone G, Marchetti A, Doglioni C, Ingravallo G, Perrone G, Parente P, **Luchini C** (corresponding author), Mastracci L. Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. *Pathologica* 2020;112:248-259.
85. Mattiolo P, Hong SM, Paolino G, Rusev BC, Marchegiani G, Salvia R, Andrianello S, Capelli P, Piccoli P, Parolini C, Scarpa A, Lawlor RT, **Luchini C**. CD117 Is a Specific Marker of Intraductal Papillary Mucinous Neoplasms (IPMN) of the Pancreas, Oncocytic Subtype. *Int J Mol Sci*. 2020;21:5794.
86. Lawlor RT, Veronese N, Pea A, Nottegar A, Smith L, Pilati C, Demurtas J, Fassan M, Cheng L, **Luchini C**. Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis. *BMC Cancer*. 2019 Mar 14;19(1):232.
87. Lawlor RT, Veronese N, Nottegar A, Malleo G, Smith L, Demurtas J, Cheng L, Wood LD, Silvestris N, Salvia R, Scarpa A, **Luchini C**. Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition. *Cancers (Basel)*. 2019;11.
88. Lawlor RT, Daprà V, Girolami I, Pea A, Pilati C, Nottegar A, Piccoli P, Parolini C, Sperandio N, Capelli P, Scarpa A, **Luchini C**. CD200 expression is a feature of solid pseudopapillary neoplasms of the pancreas. *Virchows Arch*. 2019; 474:105-109.
89. Pea A, Riva G, Bernasconi R, Sereni E, Lawlor RT, Scarpa A, **Luchini C**. Ampulla of Vater carcinoma: Molecular landscape and clinical implications. *World J Gastrointest Oncol*. 2018; 10:370-380.
90. Riva G, Pea A, Pilati C, Fiadone G, Lawlor RT, Scarpa A, **Luchini C**. Histo-molecular oncogenesis of pancreatic cancer: From precancerous lesions to invasive ductal adenocarcinoma. *World J Gastrointest Oncol*. 2018; 10(10):317-327.
91. Veronese N, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, **Luchini C**. Prognostic impact and implications of extracapsular lymph node involvement in colorectal cancer: A systematic review with meta-analysis. *Ann Oncol*. 2016;27:42-48.
92. Veronese N, Fassan M, Wood LD, Stubbs B, Solmi M, Capelli P, Pea A, Nottegar A, Sergi G, Manzato E, Carraro S, Maruzzo M, Cataldo I, Bagante F, Barbareschi M, Cheng L, Bencivenga M, de Manzoni G, **Luchini C**. Extranodal extension of nodal metastases is a poor prognostic indicator in gastric cancer: A systematic review and meta-analysis. *J Gastrointest Surg*. 2016;20:1692-1698.
93. Nottegar A, Veronese N, Senthil M, Roumen RM, Stubbs B, Choi AH, Verheuveel NC, Solmi M, Pea A, Capelli P, Fassan M, Sergi G, Manzato E, Maruzzo M, Bagante F, Koc M, Eryilmaz MA, Bria E, Carbognin L, Bonetti F, Barbareschi M, **Luchini C**. Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis. *Eur J Surg Oncol*. 2016;42:919-925.
94. Nottegar A, Veronese N, Solmi M, **Luchini C**. Tumor Suppressor Gene ARID1A in Cancer: Recent Advances and Future Perspective. *J Carinog Mutagene* 2016; 7: 255.
95. Veronese N, **Luchini C** (corresponding author), Nottegar A, Kaneko T, Sergi G, Manzato E, Solmi M, Scarpa A. Prognostic impact of extra-nodal extension in thyroid cancer: A meta-analysis. *J Surg Oncol*. 2015;112:828-833.

Commentary come ultimo autore

96. Esposito I, Haerberle L, **Luchini C**. From IPMN to invasive pancreatic cancer: new spatial insights. *Gut*. 2026 Mar 6;75(4):678-680.
97. Scarpa A, Real FX, **Luchini C**. Genetic unrelatedness of co-occurring pancreatic adenocarcinomas and IPMNs challenges current views of clinical management. *Gut*. 2018; 67(9):1561-1563.
98. Pea A, **Luchini C**. The importance of tumor microenvironment modulations in the progression of pancreatic intraductal papillary mucinous neoplasms. *J Pathol* 2025 [In Press].

Editorial come ultimo autore

99. Zen Y, **Luchini C**. Biliary adenofibroma: is it truly a benign neoplasm or benign-looking cholangiocarcinoma? *J Clin Pathol*. 2025 Jun 30:jcp-2025-210126 [Epub online ahead of print].
100. Mattiolo P, Kryklyva V, Brosens LA, Mafficini A, Lawlor RT, Milella M, Scarpa A, Corbo V, **Luchini C**. Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. *Expert Opin Ther Targets*. 2022 Jan;26(1):1-4.

Articoli come secondo/terzo autore

101. Nocini R, **Luchini C**, Mafficini A, Tondulli L, D'Ambrosio C, Biankin AV, Casolino R, Scarpa A; ICGC-ARGO; Milella M, Lawlor RT. ICGC-ARGO precision medicine: an update on immunotherapy response in metastatic head and neck squamous cell carcinoma. *Lancet Oncol*. 2025 Jun;26(6):691-692.
102. Veronese N, **Luchini C**, Ciriminna S, Spinelli K, Fruscione S, Mattiolo P, Belluzzo M, Messina V, Smith L, Barbagallo M, Mazzucco W. Potentialities and critical issues of liquid biopsy in clinical practice: An umbrella review. *Transl Oncol*. 2025 Feb;52:102172.
103. van T Veld BR, Hackeng WM, **Luchini C**, Brosens LAA, Dreijerink KMA. Clinical Relevance of ATRX/DAXX Gene Mutations and ALT in Functioning Pancreatic Neuroendocrine Tumors. *Endocr Pathol*. 2025 Feb 15;36(1):3.
104. Caldart F, de Pretis N, **Luchini C**, Ciccocioppo R, Frulloni L. Pancreatic steatosis and metabolic pancreatic disease: a new entity? *Intern Emerg Med*. 2023 Nov;18(8):2199-2208.
105. Park JH, **Luchini C**, Nottegar A, Tizaoui K, Koyanagi A, Ogino S, Shin JI, Lim BJ, Smith L. Effect of CD274 (PD-L1) overexpression on survival outcomes in 10 specific cancers: a systematic review and meta-analysis. *J Clin Pathol*. 2023 Jul;76(7):450-456.
106. Malleo G, Maggino L, **Luchini C**, Salvia R. ASO Author Reflection: Location of Nodal Metastases in Pancreatoduodenectomy for Cancer: Which Station Matters? *Ann Surg Oncol*. 2022 Jun;29(6):3489-3490.
107. Marletta S, **Luchini C**, Sperandio N, Torresani E, Sorio A, Girolami I, Scarpa A, Eccher A, Ghimenton C. CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications. *Virchows Arch*. 2022 Jun;480(6):1223-1230.
108. Park JH, Kim EY, **Luchini C**, Eccher A, Tizaoui K, Shin JI, Lim BJ. Artificial Intelligence for Predicting Microsatellite Instability Based on Tumor Histomorphology: A Systematic Review. *Int J Mol Sci*. 2022 Feb 23;23(5):2462.
109. Saeed OAM, Mann SA, **Luchini C**, Huang K, Zhang S, Sen JD, Piredda ML, Wang M, Baldrige LA, Sperling RM, Curless KL, Cheng L. Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing. *Hum Pathol*. 2021 Sep;115:10-18.
110. Bazzichetto C, Conciatori F, **Luchini C**, Simionato F, Santoro R, Vaccaro V, Corbo V, Falcone I, Ferretti G, Cognetti F, Melisi D, Scarpa A, Ciuffreda L, Milella M. From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. *Cells*. 2020;9:309.
111. Sereni E, **Luchini C**, Salvia R, Pea A. Molecular and clinical patterns of local progression in the pancreatic remnant following resection of pancreatic intraductal papillary mucinous neoplasm (IPMN). *Chin Clin Oncol*. 2019;8:21.
112. Brunetti O, **Luchini C**, Argentiero A, Tommasi S, Mangia A, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Santini D, Doglioni C, Maiello E, Lawlor RT, Mazzaferro V, Lonardi S, Giuliante F, Brandi G, Scarpa A, Cascinu S, Silvestris N. The Italian Rare Pancreatic Exocrine Cancer Initiative. *Tumori*. 2019;105:353-358.
113. Riva G, Girolami I, **Luchini C**, Villanova M, Valotto G, Cima L, Carella R, Riva M, Fraggetta F, Novelli L, Eccher A. Tracheobronchopathia Osteochondroplastica: A Case Report Illustrating the Importance of Multilevel Workup Clinical, Endoscopic and Histological Assessment in Diagnosis of an Uncommon Disease. *Am J Case Rep*. 2019;20:74-77.
114. Riva G, Mian C, **Luchini C**, Girolami I, Ghimenton C, Cima L, Novelli L, Hanspeter E, Mazzoleni G, Schwienbacher C, Pycha S, D'Elia C, Trenti E, Pycha A, Martignoni G, Hes O, Eccher A, Nesi G,

- Brunelli M. Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis. *Virchows Arch.* 2019;474:13-20.
115. Noë M, Pea A, **Luchini C**, Felsenstein M, Barbi S, Bhaijee F, Yonescu R, Ning Y, Adsay NV, Zamboni G, Lawlor RT, Scarpa A, Offerhaus GJA, Brosens LAA, Hruban RH, Roberts NJ, Wood LD. Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. *Mod Pathol.* 2018 Oct;31(10):1532-1538.
116. Nottegar A, Tabbò F, **Luchini C**, Guerrera F, Gaudiano M, Bria E, Brunelli M, Chilosi M, Inghirami G. Pulmonary adenocarcinoma with enteric differentiation: dissecting oncogenic genes alterations with DNA sequencing and FISH analysis. *Exp Mol Pathol* 2017;102:276-279.
117. Veronese N, **Luchini C**, Solmi M, Sergi G, Manzato E, Stubbs B. Monoclonal gammopathy of undetermined significance and bone health outcomes: A systematic review and exploratory meta-analysis. *J Bone Miner Metab.* 2017; 36(1):128-132.
118. Nottegar A, **Luchini C**, Cingarlini S, Beccari S, Grego E, Gilioli E, Manfrin E, Bonetti F. Pathological complete response in a patient affected by multiple synchronous, breast and lung primary malignancies: A case report and review of the literature. *Pathologica.* 2016;108:164-168.
119. De Marchi G, Paiella S, **Luchini C**, Capelli P, Bassi C, Frulloni L. Very high serum levels of CA 19-9 in autoimmune pancreatitis: Report of four cases and brief review of literature. *J Dig Dis.* 2016;17:697-702.
120. De Marchi G, Paiella S, **Luchini C**, Amodio A, Rusev B, Bassi C, Manfredi R, Frulloni L. A rare case of three different tumors in the same pancreatic specimen: A case report and brief review of the literature. *J Gastrointest Oncol.* 2016;7:E52-57.

Commentary come secondo/terzo autore

121. Kryklyva V, **Luchini C**, Stommel MWJ, Nagtegaal ID, Brosens LAA. Detecting Lynch syndrome in pancreatic ductal adenocarcinoma FNA cytology based on cancer history and immunocytochemistry. *Gut.* 2022 Jul;71(7):1450-1451.

Articoli come collaboratore

122. Holmberg M, Dall'Olio T, Marwa M, Hansen CP, Kleive DB, Nappo G, Shi L, Sandström P, Björk D, Hadesi P, De Rosa RV, Andersson B, Ansari D, Chikkala B, Todeschini L, Leseman C, Schuitema J, Lodewijks Y, Månsson C, Delis S, Berrevoet F, Giannone F, Xenaki S, Pando E, Bertrand C, Vasileiadis K, Kirchwegger P, Ciulla C, **Luchini C**, Luyer M, Besselink MG, Marchegiani G, Pandanaboyana S, Tingstedt B, Sulpice L, Wennerblom J, Björnsson B, Balakrishnan A, Labori KJ, Burgdorf SK, Qadan M, Sparrelid E, Pea A, Hernandez-Barco YG, Salvia R, Ghorbani P. Survival After Pancreatic Resection for Intraductal Papillary Mucinous Neoplasm: Supporting Selective Surgery. *United European Gastroenterol J.* 2026 Apr;14(3):e70199.
123. De Stefano F, Belfiori G, Malleo G, Lionetto G, Camisa PR, Gasparini G, Aleotti F, Cerri L, Tamburrino D, Lena MS, Casciani F, **Luchini C**, Pecorelli N, Palumbo D, Partelli S, De Cobelli F, Reni M, Salvia R, Crippa S, Falconi M. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. *Ann Surg Oncol.* 2026 Mar 23. doi: 10.1245/s10434-026-19370-1.
124. Uijterwijk BA, Lemmers DHL, Klei DS, Wilmink H, Ghidini M, Zaniboni A, Millella M, Scarpa A, **Luchini C**, Maisonneuve P, Besselink MG, Abu Hilal M. Adjuvant Chemotherapy After Curative Intent Resection of Ampullary Cancer (ADAPTA): Study Protocol for a Pan-European Prospective Multicenter Double Single Arm Trial. *Am J Clin Oncol.* 2026 Feb 6. doi: 10.1097/COC.0000000000001271. Epub ahead of print.
125. Pea A, He X, Upstill-Goddard R, **Luchini C**, Schubert Santana LP, Dreyer S, Duthie F, Jamieson NB, McKay CJ, Dickson EJ, Pulvirenti A, Rebus S, Piccoli P, Sperandio N, Lawlor RT, Milella M, Froeling FEM, Salvia R, Scarpa A, Biankin AV, Wedge DC, Chang DK. Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas. *Nat Commun.* 2026 Mar 4. doi: 10.1038/s41467-026-69762-w. Epub ahead of print.

126. De Stefano F, Belfiori G, Malleo G, Lionetto G, Camisa PR, Gasparini G, Aleotti F, Cerri L, Tamburrino D, Lena MS, Casciani F, **Luchini C**, Pecorelli N, Palumbo D, Partelli S, De Cobelli F, Reni M, Salvia R, Crippa S, Falconi M. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. *Ann Surg Oncol*. 2026 Feb 22. doi: 10.1245/s10434-026-19218-8. Epub ahead of print.
127. Parente P, Grillo F, Callegarin M, **Luchini C**, Milione M, Mattiolo P, Gafà R, Pagni F, Malapelle U, Macciomei MC, Giordano C, D'Armiento M, Ambrosio MR, Vasuri F, Fanni D, Ingravallo G, Carbone FG, Pilozzi E, Falco E, Perrone G, Caputo A, Panarese I, Pruneri G, Cassoni P, Gambella A, Savino L, Angerilli V, Vanoli A, Mastracci L, Fassan M. Adequacy criteria and reporting for prognostic and predictive profiling of biopsies from gastrointestinal neoplasia: A position paper from the Italian group of gastrointestinal pathologists, section of Italian society of anatomic pathology and cytology (GIPAD-SIAPeC-IAP). *Dig Liver Dis*. 2026 Apr;58(4):444-455.
128. Atasoy D, Saka B, Armutlu A, Mericoz CA, Bagci P, Balci S, Tezcan N, Bakkaloglu IG, Altinmakas E, Bozkurt E, Pehlivanoglu B, Bozkurtlar E, Alper E, **Luchini C**, Mafficini A, Bevere M, Scarpa A, Tellioglu G, Yilmaz S, Bilge O, Esmer R, Cheng JD, Tarcan Z, Basturk O, Reid MD, Krasinskas A, Gurses B, Adsay NV. Metatypic Carcinoma of the Pancreas: Delineation of a Clinicopathologically Distinct Entity, Characterized by Centrally Necrotic Demarcated High-Grade Carcinoma With Divergent Patterns, Basal Immunophenotype, and Altered Molecular Profile. *Am J Surg Pathol*. 2026 Apr 1;50(4):393-405.
129. Spoto F, Cardobi N, De Robertis R, Geraci L, Tomaiuolo L, Bardhi E, Mascarin B, **Luchini C**, Ruzzenente A, D'Onofrio M. Radiomics of Hepatocellular Carcinoma: Identifying Predictors of Microvascular Invasion Using Multi-Phase CT Analysis. *J Pers Med*. 2025 Nov 2;15(11):527.
130. Zordan M, Fiorio E, Maffeis V, Mafficini A, Querzoli G, Barioglio B, Biondani P, Brunelli M, Invento A, Pellini F, **Luchini C**, Scarpa A, Nottegar A. HER2-positive neuroendocrine breast carcinoma: a case study uncovers CCND1, FGF19, and IGF1R amplifications as new molecular drivers. *Pathologica*. 2025 Sep;117(4):348-356.
131. De Robertis R, Cardobi N, **Luchini C**, Pea A, Ferrari V, Scarpa A, Salvia R, D'Onofrio M. Simple mucinous cysts of the pancreas: Clinical and imaging findings - Case series and systematic review of the literature. *Eur J Radiol*. 2026 Jan;194:112501.
132. Danzi F, Butera G, Sutton D, Perricone MD, Hu Y, Celesia A, Manfredi M, Brandi J, Pourmandi N, Nelson NS, Lin L, Bevere M, Pacchiana R, Pea A, Salvia R, Scarpa A, **Luchini C**, Cecconi D, Ugel S, Lyssiotis CA, Fiore A, Donadelli M. Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. *Cell Death Dis*. 2025 Oct 27;16(1):766.
133. Angerilli V, Gasparello J, Collese A, Ceccon C, Bergamo F, Sabbadin M, Parente P, Vanoli A, Niero M, **Luchini C**, Gafà R, Dei Tos AP, Grillo F, Mastracci L, Lonardi S, Fassan M. Epstein-Barr Virus-Associated Gastric Cancer: A Histopathologic Study With Comprehensive Molecular Profiling. *Mod Pathol*. 2025 Nov;38(11):100881.
134. Wang Y, Lih TM, Lee JW, Ohtsuka T, Hozaka Y, Mino-Kenudson M, Adsay NV, **Luchini C**, Scarpa A, Maker AV, Kim GE, Paulino J, Chen L, Woo J, Jiao L, Sun Z, Goodman D, Pflüger MJ, Roberts NJ, Matthaei H, Goggins MG, Wood LD, Furukawa T, Zhang H, Hruban RH. Multi-omic profiling of intraductal papillary neoplasms of the pancreas reveals distinct patterns and potential markers of progression. *Cancer Cell*. 2025 Nov 10;43(11):2156-2170.e6.
135. Lee J, Chen F, Lopez-Beltran A, Necchi A, Cimadamore A, Spiess PE, Li R Roy-Chowdhuri S, Montironi R, Golijanin D, **Luchini C**, Cheng L. Urinary Tumor DNA (utDNA)-based Liquid Biopsy in Bladder Cancer Management: A Systematic Review. *European Urology Focus* 2025 [In Press].
136. Gasparello J, Piva VM, Angerilli V, Ceccon C, Sabbadin M, **Luchini C**, Parente P, Toffolatti L, Grillo F, Bergamo F, Malapelle U, Lonardi S, Fassan M. Lights and shadows of microsatellite status characterization in gastrointestinal cancers in the era of cancer precision therapy. *Pathologica*. 2025 Jun;117(3):204-219.
137. Vanoli A, Piva N, Inzani FS, Grillo F, Klersy C, Uccella S, Spaggiari P, Albarello L, Schiavo Lena M, Milione M, Antoniacomi C, Milanetto AC, Zerbi A, Di Sabatino A, Falconi M, Anderloni A, Mattiolo P, **Luchini C**, Scarpa A, Fassan M, Parente P, Luinetti O, Rindi G, Paulli M, La Rosa S. Clinicopathological Correlates of Hormone Expression-Based Subtypes of Non-Functioning Duodenal/Ampullary Neuroendocrine Tumors: A Multicenter Study of 151 Cases. *Endocr Pathol*. 2025 May 10;36(1):18.

138. De Pastena M, Zingaretti CC, Paiella S, Lionetto G, Guerriero M, De Santis N, **Luchini C**, Malleo G, Salvia R. Positive Lymph Nodes Independently Affect Long-Term Survival After Pancreaticoduodenectomy for Non-Ampullary Duodenal Adenocarcinoma: A Single-Center, Retrospective Analysis. *J Clin Med*. 2025 Apr 11;14(8):2616.
139. Angerilli V, Sacchi D, Rizzato M, Gasparello J, Ceccon C, Sabbadin M, Niero M, Bergamo F, Cillo U, Franzina C, **Luchini C**, Dei Tos AP, Lonardi S, Fassan M. Claudin 18.2: a promising actionable target in biliary tract cancers. *ESMO Open*. 2025 May;10(5):105049.
140. Angerilli V, Callegarin M, Govoni I, De Lisi G, Paudice M, Fugazzola P, Vanoli A, Parente P, Bergamo F, **Luchini C**, Dei Tos AP, Grillo F, Lonardi S, Mastracci L, Spolverato G, Fassan M. Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination. *Gastric Cancer*. 2025 Jul;28(4):569-578.
141. Verschuur AVD, Chen L, Nieveen van Dijkum EJ, **Luchini C**, Halfdanarson TR, Hong SM, Singhi AD, Brosens LAA, Heaphy CM. Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective. *Endocr Relat Cancer*. 2025 Apr 4;32(5):e240305.
142. Fiorini E, Malinova A, Schreyer D, Pasini D, Bevere M, Alessio G, Rosa D, D'Agosto S, Azzolin L, Milite S, Andreani S, Lupo F, Veghini L, Grimaldi S, Pedron S, Castellucci M, Nourse C, Salvia R, Malleo G, Ruzzenente A, Guglielmi A, Milella M, Lawlor RT, **Luchini C**, Agostini A, Carbone C, Pilarsky C, Sottoriva A, Scarpa A, Tuveson DA, Bailey P, Corbo V. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. *Nature*. 2025 Apr;640(8059):811-820.
143. Gasparello J, Ceccon C, Angerilli V, Comunello T, Sabbadin M, D'Almeida Costa F, Antico A, **Luchini C**, Parente P, Bergamo F, Lonardi S, Fassan M. Liquid biopsy in gastric cancer: A snapshot of the current state of the art. *J Liq Biopsy*. 2025 Jan 20;7:100288.
144. Ceccon C, Borga C, Angerilli V, Bergamo F, Munari G, Sabbadin M, Gasparello J, Schiavi F, Zovato S, Scarpa M, Urso EDL, Dei Tos AP, **Luchini C**, Grillo F, Lonardi S, Parente P, Fassan M. MLH1 gene promoter methylation status partially overlaps with CpG methylator phenotype (CIMP) in colorectal adenocarcinoma. *Pathol Res Pract*. 2025 Feb;266:155786.
145. Veghini L, Pasini D, Fang R, Delfino P, Filippini D, Neander C, Vicentini C, Fiorini E, Lupo F, D'Agosto SL, Carbone C, Agostini A, Piro G, Rosa D, Bevere M, Markus P, Behrens D, **Luchini C**, Lawlor RT, Scarpa A, Biffi G, Cheung PF, Siveke JT, Corbo V. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. *Nat Commun*. 2024 Dec 3;15(1):10534.
146. Lebedeva A, Belova E, Kavun A, Taraskina A, Bartoletti M, Bièche I, Curigliano G, Dupain C, Rios-Hoyo A, Kamal M, **Luchini C**, Poyarkov S, Le Tourneau C, Veselovsky E, Mileiko V, Ivanov M. Multi-Institutional Evaluation of Interrater Agreement of Biomarker-Drug Pair Rankings Based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and Sources of Discordance. *Mol Diagn Ther*. 2025 Jan;29(1):91-101.
147. Gálvez-Montosa F, Peduzzi G, Sanchez-Maldonado JM, Ter Horst R, Cabrera-Serrano AJ, Gentiluomo M, Macaudo A, Luque N, Ünal P, García-Verdejo FJ, Li Y, López López JA, Stein A, Bueno-de-Mesquita HB, Arcidiacono PG, Zanette DL, Kahlert C, Perri F, Soucek P, Talar-Wojnarowska R, Theodoropoulos GE, Izbicki JR, Tamás H, Van Laarhoven H, Nappo G, Petrone MC, Lovecek M, Vermeulen RCH, Adamonis K, Reyes-Zurita FJ, Holleczeck B, Sumskiene J, Mohelníková-Duchoňová B, Lawlor RT, Pezzilli R, Aoki MN, Pasquali C, Petrenkiene V, Basso D, Bunduc S, Comandatore A, Brenner H, Ermini S, Vanella G, Goetz MR, Archibugi L, Lucchesi M, Uzunoglu FG, Busch O, Milanetto AC, Puzzone M, Kupcinskis J, Morelli L, Sperti C, Carrara S, Capurso G, van Eijck CHJ, Oliverius M, Roth S, Tavano F, Kaaks R, Szentesi A, Vodickova L, **Luchini C**, Schöttker B, Landi S, Dohan O, Tacelli M, Greenhalf W, Gazouli M, Neoptolemos JP, Cavestro GM, Boggi U, Latiano A, Hegyi P, Ginocchi L, Netea MG, Sánchez-Rovira P, Canzian F, Campa D, Sainz J. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional characterization. *Int J Cancer*. 2025 Jan 15;156(2):339-352.
148. Uijterwijk BA, Lemmers DH, Moekotte AL, Zaniboni A, Ghidini M, Wilmink H, Milella M, Scarpa A, **Luchini C**, Baboeram N, Klei DS, Manzoni A, Bannone E, Oneda E, Besselink MG, Abu Hilal M; ISGACA consortium. Tackling challenges in rare diseases: The ISGACA approach on non-pancreatic cancers in the periampullary region. *Eur J Surg Oncol*. 2024 Nov;50(11):108601.
149. Yavas A, Ozcan K, Adsay NV, Balci S, Tarcan ZC, Hechtman JF, **Luchini C**, Scarpa A, Lawlor RT, Mafficini A, Reid MD, Xue Y, Yang Z, Haye K, Bellizzi AM, Vanoli A, Benhamida J, Balachandran V, Jarnagin W, Park W, O'Reilly EM, Klimstra DS, Basturk O. SWI/SNF Complex-Deficient

- Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis. *Mod Pathol.* 2024 Nov;37(11):100585.
150. Paiella S, Landoni L, De Pastena M, Elio G, Casciani F, Cingarlini S, D'Onofrio M, Maistri G, Ciatti I, Tuveri M, Davì MV, **Luchini C**, Donadello K, Manzini G, Malleo G, Salvia R. Surgery for pancreatic neuroendocrine tumors during the COVID-19 pandemic: a retrospective cohort from a high-volume center. *Updates Surg.* 2024 Sep;76(5):1827-1832.
151. Eren OC, Bagci P, Balci S, Ohike N, Saka B, Sokmensuer C, Leblebici CB, Xue Y, Reid MD, Krasinskas AM, Kooby D, Maithel SK, Sarmiento J, Cheng JD, Taskin OC, Kapran Y, Tarcan Z, **Luchini C**, Scarpa A, Basturk O, Adsay NV. ASO Author Reflections: Prognostic Value of Subgrading G2 Pancreatic Neuroendocrine Tumors as 2A versus 2B. *Ann Surg Oncol.* 2024 Oct;31(10):7068-7069.
152. Eren OC, Bagci P, Balci S, Ohike N, Saka B, Sokmensuer C, Leblebici CB, Xue Y, Reid MD, Krasinskas AM, Kooby D, Maithel SK, Sarmiento J, Cheng JD, Taskin OC, Kapran Y, Tarcan ZC, **Luchini C**, Scarpa A, Basturk O, Adsay NV. Subgrading of G2 Pancreatic Neuroendocrine Tumors as 2A (Ki67 3% to < 10%) Versus 2B (10% to ≤ 20%) Identifies Behaviorally Distinct Subsets in Keeping with the Evolving Management Protocols. *Ann Surg Oncol.* 2024 Oct;31(10):7001-7011.
153. Alors-Pérez E, Blázquez-Encinas R, Moreno-Montilla MT, García-Vioque V, Jiménez-Vacas JM, Mafficini A, González-Borja I, **Luchini C**, Sánchez-Hidalgo JM, Sánchez-Frías ME, Pedraza-Arevalo S, Romero-Ruiz A, Lawlor RT, Viúdez A, Gahete MD, Scarpa A, Arjona-Sánchez Á, Luque RM, Ibáñez-Costa A, Castaño JP. Spliceosomal dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets. *Mol Oncol.* 2024 Oct;18(10):2524-2540.
154. Borghesani M, Reni A, Lauricella E, Rossi A, Moscarda V, Trevisani E, Torresan I, Al-Toubah T, Filoni E, **Luchini C**, De Robertis R, Landoni L, Scarpa A, Porta C, Milella M, Strosberg J, Cives M, Cingarlini S. Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. *J Natl Compr Canc Netw.* 2024 May 14;22(5):e247005.
155. Faber EB, Krause HB, Amin K, Walker P, Hosein PJ, Shields AF, Lenz HJ, Prakash A, Goel S, Oberley M, Malleo G, **Luchini C**, Hwang J, Florou V, Garrido-Laguna I, Lou E. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets. *JCO Precis Oncol.* 2024 May;8:e2300595.
156. Malleo G, Lionetto G, Crippa S, Qadan M, Moser G, Belfiori G, Scarpa A, Schiavo-Lena M, Casciani F, Mattiolo P, Paiella S, Esposito A, **Luchini C**, Ferrone CR, Lillemo KD, Fernández-Del Castillo C, Falconi M, Salvia R. Reappraising the Role of Intraoperative Neck Margin Revision in Post-Neoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis. *Ann Surg.* 2024 Epub ahead of print.
157. Balzo GD, Pelletti G, Raniero D, Farinelli A, Uberti A, Vermiglio E, Molteni G, Nocini R, Gobbo S, Taus F, Eccher A, **Luchini C**, Brunelli M. Forensic value of soft tissue detachments from the hyoid bone in death due to strangulation asphyxia. *Adv Clin Exp Med.* 2025 Mar;34(3):327-335.
158. Angerilli V, Vanoli A, Celin G, Cecon C, Gasparello J, Sabbadin M, De Lisi G, Paudice M, Lenti MV, Rovedatti L, Di Sabatino A, Bazzocchi F, Lonardi S, Savarino E, **Luchini C**, Parente P, Grillo F, Mastracci L, Fassan M. Gastric Carcinoma in Autoimmune Gastritis: A Histopathologic and Molecular Study. *Mod Pathol.* 2024 Jun;37(6):100491.
159. Verschuur AVD, Hackeng WM, Westerbeke F, Benhamida JK, Basturk O, Selenica P, Raicu GM, Molenaar IQ, van Santvoort HC, Daamen LA, Klimstra DS, Yachida S, **Luchini C**, Singhi AD, Geisenberger C, Brosens LAA. DNA Methylation Profiling Enables Accurate Classification of Noductal Primary Pancreatic Neoplasms. *Clin Gastroenterol Hepatol.* 2024 Jun;22(6):1245-1254.e10.
160. Speranza D, Sapuppo E, Aprile G, Auriemma A, Bergamo F, Bianco R, Bordonaro R, Brandi G, Brunetti O, Carnaghi C, Ciliberto D, Cinieri S, Corallo S, De Vita F, Di Donato S, Ferrà F, Fornaro L, Barucca V, Giommoni E, Lotesoriere C, Luchini C, Masini C, Niger M, Pisconti S, Rapposelli IG, Rimassa L, Rognone C, Rodriquenz MG, Corsini LR, Santin D, Scarpa A, Scartozzi M, Soto Parra H, Tonini G, Tortora G, Tralongo P, Silvestris N. The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO). *Tumori.* 2024 Jun;110(3):203-208.

161. Angerilli V, Ghelardi F, Nappo F, Grillo F, Parente P, Lonardi S, **Luchini C**, Pietrantonio F, Ugolini C, Vanoli A, Fassan M. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion. *Pathol Res Pract*. 2024 Feb;254:155145.
162. Grillo F, Angerilli V, Parente P, Vanoli A, **Luchini C**, Sciallero S, Puccini A, Bergamo F, Lonardi S, Valeri N, Mastracci L, Fassan M. Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting. *Virchows Arch*. 2024 Jul;485(1):131-135.
163. De Pastena M, Zingaretti CC, Paiella S, Guerriero M, De Santis N, **Luchini C**, Bassi C, Malleo G, Salvia R. Impact of extra-ampullary duodenal adenocarcinoma subtypes on surgical and oncological outcomes following pancreaticoduodenectomy. *Updates Surg*. 2024 Jan;76(1):87-95.
164. Melisi D, Zecchetto C, Merz V, Malleo G, Landoni L, Quinzii A, Casalino S, Fazzini F, Gaule M, Pesoni C, Casetti L, Esposito A, Marchegiani G, Piazzola C, D'Onofrio M, de Robertis R, Gabbrielli A, Bernardoni L, Crino SF, Pietrobono S, **Luchini C**, Aliberti C, Martignoni G, Milleri S, Butturini G, Scarpa A, Salvia R, Bassi C. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. *Eur J Cancer*. 2024 Jan;196:113430.
165. Wood LD, Adsay NV, Basturk O, Brosens LAA, Fukushima N, Hong SM, Kim SJ, Lee JW, **Luchini C**, Noë M, Pitman MB, Scarpa A, Singhi AD, Tanaka M, Furukawa T. Systematic review of challenging issues in pathology of intraductal papillary mucinous neoplasms. *Pancreatology*. 2023 Nov;23(7):878-891.
166. Nocini R, Tondulli L, D'Ambrosio C, **Luchini C**, Biankin AV, Casolino R, Scarpa A; ICGC-ARGO; Milella M, Lawlor RT. ICGC ARGO precision medicine: genomic profiling-informed prediction of immunotherapy response in two patients with metastatic head and neck squamous cell carcinoma. *Lancet Oncol*. 2023 Aug;24(8):851-853.
167. Mattiolo P, Gkoutakos A, Centonze G, Bevere M, Piccoli P, Ammendola S, Pedrazzani C, Landoni L, Cingarlini S, Milella M, Milione M, **Luchini C**, Scarpa A, Simbolo M. Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups. *Pathol Res Pract*. 2023 Aug;248:154674.
168. Perri G, Marchegiani G, Partelli S, Andreasi V, **Luchini C**, Bariani E, Bannone E, Fermi F, Mattiolo P, Falconi M, Salvia R, Bassi C. Either High or Low Risk: The Acinar Score at the Resection Margin Dichotomizes the Risk Spectrum of Pancreas-specific Complications After Pancreatoduodenectomy. *Ann Surg*. 2023 Dec 1;278(6):e1242-e1249.
169. Maggino L, Malleo G, Crippa S, Belfiori G, Bannone E, Lionetto G, Gasparini G, Nobile S, **Luchini C**, Mattiolo P, Schiavo-Lena M, Doglioni C, Scarpa A, Ferrone C, Bassi C, Fernández-Del Castillo C, Falconi M, Salvia R. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. *Br J Surg*. 2023 Jul 17;110(8):973-982.
170. Mastrosimini MG, Manfrin E, Remo A, De Bellis M, Parisi A, Pedron S, **Luchini C**, Brunelli M, Ammendola S, Bernardoni L, Conti Bellocchi MC, Gabbrielli A, Facciorusso A, Pea A, Landoni L, Scarpa A, Crinò SF. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors. *Pancreatology*. 2023 Jun;23(4):429-436.
171. Campa D, Gentiluomo M, Stein A, Aoki MN, Oliverius M, Vodičková L, Jamroziak K, Theodoropoulos G, Pasquali C, Greenhalf W, Arcidiacono PG, Uzunoglu F, Pezzilli R, **Luchini C**, Puzzone M, Loos M, Giaccherini M, Katzke V, Mambrini A, Kiudeliene E, Federico KE, Johansen J, Hussein T, Mohelnikova-Duchonova B, van Eijck CHJ, Brenner H, Farinella R, Pérez JS, Lovecek M, Büchler MW, Hlavac V, Izbicki JR, Hackert T, Chammas R, Zerbi A, Lawlor R, Felici A, Götz M, Capurso G, Ginocchi L, Gazouli M, Kupcinskas J, Cavestro GM, Vodicka P, Moz S, Neoptolemos JP, Kunovsky L, Bojesen SE, Carrara S, Gioffreda D, Morkunas E, Abian O, Bunduc S, Basso D, Boggi U, Włodarczyk B, Szentesi A, Vanella G, Chen I, Bijlsma MF, Kiudelis V, Landi S, Schöttker B, Corradi C, Giese N, Kaaks R, Peduzzi G, Hegyi P, Morelli L, Furbetta N, Soucek P, Latiano A, Talar-Wojnarowska R, Lindgaard SC, Dijk F, Milanetto AC, Tavano F, Cervena K, Eröss B, Testoni SG, Verhagen-Oldenampsen JHE, Małecka-Wojcieszko E, Costello E, Salvia R, Maiello E, Ermini S, Sperti C, Holleczyk B, Perri F, Skieceviciene J, Archibugi L, Lucchesi M, Rizzato C, Canzian F. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of

- association studies to understand the genetic architecture of pancreatic cancer. *Crit Rev Oncol Hematol.* 2023 Jun;186:104020.
172. D'Agosto S, Fiorini E, Pezzini F, Delfino P, Simbolo M, Vicentini C, Andreani S, Capelli P, Rusev B, Lawlor RT, Bassi C, Landoni L, Pea A, **Luchini C**, Scarpa A, Corbo V. Long-term organoid culture of a small intestinal neuroendocrine tumor. *Front Endocrinol (Lausanne).* 2023 Apr 4;14:999792.
173. Nodari Y, Gentiluomo M, Mohelnikova-Duchonova B, Kreivenaite E, Milanetto AC, Skieceviciene J, Landi S, Lawlor RT, Petrone MC, Arcidiacono PG, Lovecek M, Gazouli M, Bijlsma MF, Morelli L, Kiudelis V, Tacelli M, Zanette DL, Soucek P, Uzunoglu F, Kaaks R, Izbicki J, Boggi U, Pezzilli R, Mambrini A, Pasquali C, van Laarhoven HW, Katzke V, Cavestro GM, Sperti C, Loos M, Latiano A, Eröss B, Oliverius M, Johnson T, Basso D, Neoptolemos JP, Aoki MN, Greenhalf W, Vodicka P, Archibugi L, Vanella G, Lucchesi M, Talar-Wojnarowska R, Jamroziak K, Saeedi MA, van Eijck CHJ, Kupcinskis J, Hussein T, Puzzono M, Bunduc S, Götz M, Carrara S, Szentesi A, Tavano F, Moz S, Hegyi P, **Luchini C**, Capurso G, Perri F, Ermini S, Theodoropoulos G, Capretti G, Palmieri O, Ginocchi L, Furbetta N, Canzian F, Campa D. Genetic and non-genetic risk factors for early-onset pancreatic cancer. *Dig Liver Dis.* 2023 Oct;55(10):1417-1425.
174. Bevere M, Gkoutakos A, Martelli FM, Scarpa A, **Luchini C**, Simbolo M. An Insight on Functioning Pancreatic Neuroendocrine Neoplasms. *Biomedicines.* 2023 Jan 21;11(2):303.
175. Malleo G, Maggino L, Lionetto G, Patton A, Paiella S, Pea A, Esposito A, Casetti L, **Luchini C**, Scarpa A, Bassi C, Salvia R. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. *Surgery.* 2023 Apr;173(4):1030-1038.
176. Sapuppo E, Brunetti O, Tessitore D, Brandi G, Di Giovanni N, Fadda G, **Luchini C**, Martini M, Quaresmini D, Russo A, Santarpia M, Scarpa A, Scartozzi M, Tuccari G, Franchina T, Silvestris N. Rare histotypes of epithelial biliary tract tumors: A literature review. *Crit Rev Oncol Hematol.* 2023 Jan;181:103892.
177. Cappello F, Angerilli V, Dal Santo L, Munari G, Sabbadin M, Lo Mele M, Pennelli G, **Luchini C**, Parente P, Lazzi S, Fassan M. Morphological and molecular characterization of colorectal sessile serrated lesions with dysplasia. *Pathol Res Pract.* 2022 Dec;240:154214.
178. Janssen BV, van Roessel S, van Dieren S, de Boer O, Adsay V, Basturk O, Brosens L, Campbell F, Chatterjee D, Chou A, Doglioni C, Esposito I, Feakins R, Fuchs TL, Fukushima N, Gill AJ, Hong SM, Hruban RH, Kaplan J, Krasinkas A, **Luchini C**, Shi C, Singhi A, Thompson E, Velthuysen MF, Besselink MG, Verheij J, Wang H, Verbeke C, Fariña A; International Study Group of Pancreatic Pathologists (ISGPP). Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). *Br J Surg.* 2022 Dec 13;110(1):67-75.
179. Maggino L, Malleo G, Crippa S, Belfiori G, Nobile S, Gasparini G, Lionetto G, **Luchini C**, Mattiolo P, Schiavo-Lena M, Doglioni C, Scarpa A, Bassi C, Falconi M, Salvia R. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. *Ann Surg Oncol.* 2023 Jan;30(1):207-219.
180. Pollini T, Adsay V, Capurso G, Dal Molin M, Esposito I, Hruban R, **Luchini C**, Maggino L, Matthaei H, Marchegiani G, Scarpa A, Wood LD, Bassi C, Salvia R, Mino-Kenudson M, Maker AV. The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms. *Lancet Gastroenterol Hepatol.* 2022 Dec;7(12):1141-1150.
181. Munari E, Querzoli G, Brunelli M, Marconi M, Sommaggio M, Cocchi MA, Martignoni G, Netto GJ, Calì A, Quatrini L, Mariotti FR, **Luchini C**, Girolami I, Eccher A, Segala D, Ciompi F, Zamboni G, Moretta L, Bogina G. Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection. *Front Immunol.* 2022 Jul 27;13:954910.
182. D'Agosto S, Pezzini F, Veghini L, Delfino P, Fiorini C, Temgue Tane GD, Del Curatolo A, Vicentini C, Ferrari G, Pasini D, Andreani S, Lupo F, Fiorini E, Lorenzon G, Lawlor RT, Rusev B, Malinova A, **Luchini C**, Milella M, Sereni E, Pea A, Bassi C, Bailey P, Scarpa A, Bria E, Corbo V. Loss of FGFR4 promotes the malignant phenotype of PDAC. *Oncogene.* 2022 Sep;41(38):4371-4384.
183. Angerilli V, Pennelli G, Galuppini F, Realdon S, Fantin A, Savarino E, Farinati F, Mastracci L, **Luchini C**, Fassan M. Molecular subtyping of gastroesophageal dysplasia heterogeneity according to TCGA/ACRG classes. *Virchows Arch.* 2022 Oct;481(4):545-552.

184. Pedrazzani C, Conti C, Di Vittori A, Turri G, Bernardoni L, Mafficini A, **Luchini C**, Gabbrielli A, Scarpa A, Guglielmi A. Video technical notes for approaching a unique case of Juvenile Polyposis with massive gastric ingrowth. *Asian J Surg.* 2023 Feb;46(2):924-925.
185. Milella M, Lawlor RT, **Luchini C**, Johns AL; ICGC-ARGO; Casolino R, Yoshino T, Biankin AV, Scarpa A. ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. *Lancet Oncol.* 2022 Aug;23(8):991-992.
186. Marletta S, Fusco N, Munari E, **Luchini C**, Cimadamore A, Brunelli M, Querzoli G, Martini M, Vigliar E, Colombari R, Girolami I, Pagni F, Eccher A. Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. *J Pers Med.* 2022 Jun 29;12(7):1073.
187. Biancotti R, Dal Pozzo CA, Parente P, Businello G, Angerilli V, Realdon S, Savarino EV, Farinati F, Milanetto AC, Pasquali C, Vettor R, Grillo F, Pennelli G, **Luchini C**, Mastracci L, Vanoli A, Milione M, Galuppini F, Fassan M. Histopathological Landscape of Precursor Lesions of Gastro-Enteropancreatic Neuroendocrine Neoplasms. *Dig Dis.* 2023;41(1):34-48.
188. Reissig TM, Uhrig S, Jost PJ, **Luchini C**, Vicentini C, Liffers ST, Allgäuer M, Adsay V, Scarpa A, Lawlor RT, Fröhling S, Stenzinger A, Klöppel G, Schildhaus HU, Siveke JT. MCL1 as putative target in pancreatoblastoma. *Virchows Arch.* 2022 Aug;481(2):265-272.
189. Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, Genuardi M, Turchetti D, De Giorgi U, Di Maio M, Barberis M, Dessena M, Del Re M, Lapini A, **Luchini C**, Jereczek-Fossa BA, Sapino A, Cinieri S; Italian Scientific Societies. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. *ESMO Open.* 2022 Jun;7(3):100459.
190. Vanoli A, Grami O, Klersy C, Milanetto AC, Albarello L, Fassan M, **Luchini C**, Grillo F, Spaggiari P, Inzani F, Uccella S, Parente P, Nappo G, Mattiolo P, Milione M, Pietrabissa A, Cobianchi L, Schiavo Lena M, Partelli S, Di Sabatino A, Sempoux C, Capella C, Pasquali C, Doglioni C, Sessa F, Scarpa A, Rindi G, Paulli M, Zerbi A, Falconi M, Solcia E, La Rosa S. Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases. *Endocr Pathol.* 2022 Jun;33(2):274-288.
191. Poletto E, Ruzzenente A, Turri G, Conci S, Ammendola S, **Luchini C**, Scarpa A, Guglielmi A. Surgical treatment of ductal biliary recurrence of poorly cohesive gastric cancer mimicking primary biliary tract cancer: a case report. *J Surg Case Rep.* 2022 Apr 11;2022(4):rjac132.
192. Tsvetkova V, Magro G, Broggi G, **Luchini C**, Cappello F, Caporalini C, Buccoliero AM, Santoro L. New insights in gastrointestinal "pediatric" neoplasms in adult patients: pancreatoblastoma, hepatoblastoma and embryonal sarcoma of the liver. A practical approach by GIPPI-GIPAD Groups. *Pathologica.* 2022 Feb;114(1):64-78.
193. Pietrasz D, Sereni E, Lancelotti F, Pea A, **Luchini C**, Innamorati G, Salvia R, Bassi C. Circulating tumour DNA: a challenging innovation to develop "precision onco-surgery" in pancreatic adenocarcinoma. *Br J Cancer.* 2022 Jun;126(12):1676-1683.
194. Malleo G, Maggino L, Casciani F, Lionetto G, Nobile S, Lazzarin G, Paiella S, Esposito A, Capelli P, **Luchini C**, Scarpa A, Bassi C, Salvia R. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol. *Ann Surg Oncol.* 2022 Jun;29(6):3477-3488.
195. Tuveri M, Paiella S, Boschi F, **Luchini C**, Perri G, Gasparini C, Aresta A, Scarpa A, Salvia R, Bassi C. Evidence of glucose absorption in a neofomed intestine. *Updates Surg.* 2022 Oct;74(5):1705-1713.
196. Taskin OC, Reid MD, Bagci P, Balci S, Armutlu A, Demirtas D, Pehlivanoglu B, Saka B, Memis B, Bozkurtlar E, Leblebici CB, Birceanu A, Xue Y, Erkan M, Kapran Y, Baygul A, Sokmensuer C, Scarpa A, **Luchini C**, Basturk O, Adsay V. Infiltration pattern predicts metastasis and progression better than the T-stage and grade in pancreatic neuroendocrine tumors: a proposal for a novel infiltration-based morphologic grading. *Mod Pathol.* 2022 Jun;35(6):777-785.
197. Wang H, Chetty R, Hosseini M, Allende DS, Esposito I, Matsuda Y, Deshpande V, Shi J, Dhall D, Jang KT, Kim GE, **Luchini C**, Graham RP, Reid MD, Basturk O, Hruban RH, Krasinskas A, Klimstra DS, Adsay V; Pancreatobiliary Pathology Society. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society. *Am J Surg Pathol.* 2022 Jun 1;46(6):754-764.
198. Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, Nieveen van Dijkum E,

- Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Hogg M, Lee K, Geller D, Marsh JW, Paniccia A, Ongchin M, Pingpank JF, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella KE, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova MN, Lawlor RT, Mafficini A, Rusev B, Corbo V, **Luchini C**, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong SM, Heaphy CM, Singhi AD. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. *Gut*. 2022 May;71(5):961-973.
199. Alors-Perez E, Blázquez-Encinas R, Alcalá S, Viyuela-García C, Pedraza-Arevalo S, Herrero-Aguayo V, Jiménez-Vacas JM, Mafficini A, Sánchez-Frías ME, Cano MT, Abollo-Jiménez F, Marín-Sanz JA, Cabezas-Sainz P, Lawlor RT, **Luchini C**, Sánchez L, Sánchez-Hidalgo JM, Ventura S, Martín-Hijano L, Gahete MD, Scarpa A, Arjona-Sánchez Á, Ibáñez-Costa A, Sainz B Jr, Luque RM, Castaño JP. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. *J Exp Clin Cancer Res*. 2021 Dec 2;40(1):382.
200. Silvestris N, Argentiero A, Brunetti O, Sonnessa M, Colonna F, Delcuratolo S, **Luchini C**, Scarpa A, Lonardi S, Nappo F, Fassan M, Solimando AG, Fucci L, Saponaro C. PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study. *Expert Opin Ther Targets*. 2021 Nov;25(11):1007-1016.
201. Lee HJ, Jeong GH, Li H, Kim MS, Kim JS, Park SJ, Han YJ, Lee KH, Kronbichler A, Hong SH, Ghayda RA, **Luchini C**, Nottegar A, Koyanagi A, Smith L, Jacob L, Dragioti E, Radua J, Cargnin S, Terrazzino S, Thompson T, Yon DK, Lee SW, Yang JM, Wasuwanich P, Shin JI, Gamerith G. Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis. *Eur Rev Med Pharmacol Sci*. 2021 Oct;25(20):6232-6244.
202. Frizziero M, Durand A, Taboada RG, Zaninotto E, **Luchini C**, Chakrabarty B, Hervieu V, Claro LCL, Zhou C, Cingarlini S, Milella M, Walter T, Riechelmann RS, Lamarca A, Hubner RA, Mansoor W, Valle JW, McNamara MG. Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant? *Cancers (Basel)*. 2021 Aug 18;13(16):4152.
203. Marchegiani G, Andrianello S, Crippa S, Pollini T, Belfiori G, Gozzini L, Cassalia F, Caravati A, **Luchini C**, Doglioni C, Bassi C, Falconi M, Salvia R. Actual malignancy risk of either operated or non-operated presumed mucinous cystic neoplasms of the pancreas under surveillance. *Br J Surg*. 2021 Sep 27;108(9):1097-1104.
204. Simbolo M, Bilotta M, Mafficini A, **Luchini C**, Furlan D, Inzani F, Petrone G, Bonvissuto D, La Rosa S, Schinzari G, Bianchi A, Rossi E, Menghi R, Giuliante F, Boccia S, Scarpa A, Rindi G. Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades. *Cancers (Basel)*. 2021 Apr 23;13(9):2054.
205. Marchegiani G, Perri G, Burelli A, Zoccatelli F, Andrianello S, **Luchini C**, Donadello K, Bassi C, Salvia R. High-risk Pancreatic Anastomosis Versus Total Pancreatectomy After Pancreatoduodenectomy: Postoperative Outcomes and Quality of Life Analysis. *Ann Surg*. 2022 Dec 1;276(6):e905-e913.
206. Bagante F, Spolverato G, Ruzzenente A, **Luchini C**, Tsilimigras DI, Campagnaro T, Conci S, Corbo V, Scarpa A, Guglielmi A, Pawlik TM. Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data. *Eur J Cancer*. 2021 Mar 25;148:348-358.
207. Munari G, Businello G, Mattiolo P, Pennelli G, Sbaraglia M, Borga C, Pucciarelli S, Spolverato G, Mescoli C, Galuppini F, Sommariva A, Bellan E, Lonardi S, Loupakis F, **Luchini C**, Dei Tos AP, Fassan M. Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience. *J Cancer Res Clin Oncol*. 2021 Jul;147(7):1897-1904.
208. van Roessel S, Janssen BV, Soer EC, Fariña Sarasqueta A, Verbeke CS, **Luchini C**, Brosens LAA, Verheij J, Besselink MG. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review. *Br J Surg*. 2021 Mar 12;108(2):119-127.
209. Pulvirenti A, Raj N, Cingarlini S, Pea A, Tang LH, **Luchini C**, Chou JF, Grego E, Marinova I, Capanu M, Landoni L, Scarpa A, Allen PJ, Klimstra DS, Reidy-Lagunes DL. Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms. *Pancreas*. 2021 Feb 1;50(2):138-146.

210. Lakis V, Lawlor RT, Newell F, Patch AM, Mafficini A, Sadanandam A, Koufariotis LT, Johnston RL, Leonard C, Wood S, Rusev B, Corbo V, **Luchini C**, Cingarlini S, Landoni L, Salvia R, Milella M, Chang D, Bailey P, Jamieson NB, Duthie F, Gingras MC, Muzny DM, Wheeler DA, Gibbs RA, Milione M; APCI; ARC-Net, Pederzoli P, Samra JS, Gill AJ, Johns AL, Pearson JV, Biankin AV, Grimmond SM, Waddell N, Nones K, Scarpa A. DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. *Commun Biol.* 2021 Feb 3;4(1):155.
211. Corradi C, Gentiluomo M, Gajdán L, Cavestro GM, Kreivenaite E, Di Franco G, Sperti C, Giaccherini M, Petrone MC, Tavano F, Gioffreda D, Morelli L, Soucek P, Andriulli A, Izbicki JR, Napoli N, Małecká-Panas E, Hegyi P, Neoptolemos JP, Landi S, Vashist Y, Pasquali C, Lu Y, Cervena K, Theodoropoulos GE, Moz S, Capurso G, Strobel O, Carrara S, Hackert T, Hlavac V, Archibugi L, Oliverius M, Vanella G, Vodicka P, Arcidiacono PG, Pezzilli R, Milanetto AC, Lawlor RT, Ivanauskas A, Szentesi A, Kupcinskas J, Testoni SGG, Lovecek M, Nentwich M, Gazouli M, **Luchini C**, Zuppardo RA, Darvasi E, Brenner H, Gheorghe C, Jamroziak K, Canzian F, Campa D. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. *Int J Cancer.* 2021 Jun 1;148(11):2779-2788.
212. Milanetto AC, Tonello AS, Valotto G, Munari G, **Luchini C**, Fassan M, Pasquali C. Simple mucinous cyst: another potential cancer precursor in the pancreas? Case report with molecular characterization and systematic review of the literature. *Virchows Arch.* 2021 Jul;479(1):179-189.
213. Demurtas J, Fanelli GN, Romano SL, Solari M, Yang L, Soysal P, López Sánchez GF, Grabovac I, Smith L, Zorzi A, **Luchini C**, Veronese N. Stem cells for treatment of cardiovascular diseases: An umbrella review of randomized controlled trials. *Ageing Res Rev.* 2021 May;67:101257.
214. Cobo I, Iglesias M, Flández M, Verbeke C, Del Pozo N, Llorente M, Lawlor R, **Luchini C**, Rusev B, Scarpa A, Real FX. Epithelial Nr5a2 heterozygosity cooperates with mutant Kras in the development of pancreatic cystic lesions. *J Pathol.* 2021 Feb;253(2):174-185.
215. Janssen BV, Tutucu F, van Roessel S, Adsay V, Basturk O, Campbell F, Doglioni C, Esposito I, Feakins R, Fukushima N, Gill AJ, Hruban RH, Kaplan J, Koerkamp BG, Hong SM, Krasinskas A, **Luchini C**, Offerhaus J, Sarasqueta AF, Shi C, Singhi A, Stoop TF, Soer EC, Thompson E, van Tienhoven G, Velthuysen MF, Wilmink JW, Besselink MG, Brosens LAA, Wang H, Verbeke CS, Verheij J; International Study Group of Pancreatic Pathologists (ISGPP). Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. *Mod Pathol.* 2021 Jan;34(1):4-12.
216. Zhang B, Lee GC, Qadan M, Fong ZV, Mino-Kenudson M, Desphande V, Malleo G, Maggino L, Marchegiani G, Salvia R, Scarpa A, **Luchini C**, De Gregorio L, Ferrone CR, Warshaw AL, Lillemoen KD, Bassi C, Castillo CF. Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. *Ann Surg.* 2021 Aug 1;274(2):e134-e142.
217. Young K, Lawlor RT, Ragulan C, Patil Y, Mafficini A, Bersani S, Antonello D, Mansfield D, Cingarlini S, Landoni L, Pea A, **Luchini C**, Piredda L, Kannan N, Nyamundanda G, Morganstein D, Chau I, Wiedenmann B, Milella M, Melcher A, Cunningham D, Starling N, Scarpa A, Sadanandam A. Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. *Gut* 2020, Epub ahead of print.
218. Noë M, Niknafs N, Fischer CG, Hackeng WM, Beleva Guthrie V, Hosoda W, Debeljak M, Papp E, Adleff V, White JR, **Luchini C**, Pea A, Scarpa A, Butturini G, Zamboni G, Castelli P, Hong SM, Yachida S, Hiraoka N, Gill AJ, Samra JS, Offerhaus GJA, Hoorens A, Verheij J, Jansen C, Adsay NV, Jiang W, Winter J, Albores-Saavedra J, Terris B, Thompson ED, Roberts NJ, Hruban RH, Karchin R, Scharpf RB, Brosens LAA, Velculescu VE, Wood LD. Genomic characterization of malignant progression in neoplastic pancreatic cysts. *Nat Commun.* 2020;11:4085.
219. Kryklyva V, Ter Linden E, Kroeze LI, de Voer RM, van der Kolk BM, Stommel MWJ, Hermans JJ, **Luchini C**, Wood LD, Hruban RH, Nagtegaal ID, Ligtenberg MJL, Brosens LAA. Medullary Pancreatic Carcinoma Due to Somatic POLE Mutation: A Distinctive Pancreatic Carcinoma With Marked Long-Term Survival. *Pancreas.* 2020;49:999-1003.
220. Eccher A, Girolami I, Brunelli M, Novelli L, Mescoli C, Malvi D, D'Errico A, **Luchini C**, Furian L, Zaza G, Cardillo M, Boggi U, Pantanowitz L. Digital pathology for second opinion consultation and donor assessment during organ procurement: Review of the literature and guidance for deployment in transplant practice. *Transplant Rev (Orlando)* 2020;34:100562.

221. Esposito I, Hruban RH, Verbeke C, Terris B, Zamboni G, Scarpa A, Morohoshi T, Suda K, **Luchini C**, Klimstra DS, Adsay V, Haeberle L, Saluja A, Fernandez-Del Castillo C, Sheel A, Neoptolemos JP, Isaji S, Shimosegawa T, Whitcomb DC, Campbell F; Working group for the International (IAP – APA – JPS – EPC) Consensus Guidelines for Chronic Pancreatitis. Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club. *Pancreatology*. 2020;20:586-593.
222. Huang W, Navarro-Serer B, Jeong YJ, Chianchiano P, Xia L, **Luchini C**, Veronese N, Dowiak C, Ng T, Trujillo MA, Huang B, Pflüger MJ, Macgregor-Das AM, Lionheart G, Jones D, Fujikura K, Nguyen-Ngoc KV, Neumann NM, Groot VP, Hasanain A, van Oosten AF, Fischer SE, Gallinger S, Singhi AD, Zureikat AH, Brand RE, Gaida MM, Heinrich S, Burkhart RA, He J, Wolfgang CL, Goggins MG, Thompson ED, Roberts NJ, Ewald AJ, Wood LD. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. *Cancer Res*. 2020;80:2804-2817.
223. Vicentini C, Calore F, Nigita G, Fadda P, Simbolo M, Sperandio N, **Luchini C**, Lawlor RT, Croce CM, Corbo V, Fassan M, Scarpa A. Exosomal miRNA signatures of pancreatic lesions. *BMC Gastroenterol*. 2020;20:137.
224. Malleo G, Maggino L, Nobile S, Casciani F, Cacciatori N, Paiella S, **Luchini C**, Rusev B, Capelli P, Marchegiani G, Bassi C, Salvia R. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma. *Eur J Surg Oncol*. 2020;46:1734-1741.
225. Malleo G, Maggino L, Ferrone CR, Marchegiani G, **Luchini C**, Mino-Kenudson M, Paiella S, Qadan M, Scarpa A, Lillemoe KD, Bassi C, Fernández-Del Castillo C, Salvia R. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. *Ann Surg Oncol*. 2020;27:3898-3912.
226. Larghi A, Lawlor RT, Crinò SF, **Luchini C**, Rizzatti G, Curatolo M, Gabbrielli A, Inzani F, Scarpa A. Endoscopic ultrasound guided fine needle biopsy samples to drive personalized medicine: A proof of concept study. *Pancreatology*. 2020;20(4):778-780.
227. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. *Nature*. 2020;578:82-93.
228. Fassan M, Brignola S, Pennelli G, Alberti G, Angerilli V, Bressan A, Pellino A, Lanza C, Salmaso R, Lonardi S, Pucciarelli S, Spolverato G, Scarpa M, Realdon S, Farinati F, **Luchini C**, Rugge M, Loupakis F. PD-L1 expression in gastroesophageal dysplastic lesions. *Virchows Arch*. 2020;477:151-156.
229. Kim JY, Lee KH, Kang J, Borcoman E, Saada-Bouzzid E, Kronbichler A, Hong SH, de Rezende LFM, Ogino S, Keum N, Song M, **Luchini C**, van der Vliet HJ, Shin JI, Gernerith G. Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2019;11:1699.
230. Bagante F, Ruzzenente A, Conci S, Rusev BC, Simbolo M, Campagnaro T, Pawlik TM, **Luchini C**, Iacono C, Scarpa A, Guglielmi A. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification? *HPB (Oxford)*. 2019;21:1648-1655.
231. Pea A, Yu J, Marchionni L, Noe M, **Luchini C**, Pulvirenti A, de Wilde RF, Brosens LA, Rezaee N, Javed A, Gobbo S, Regi P, Salvia R, Bassi C, He J, Weiss MJ, Cameron JL, Offerhaus GJA, Hruban RH, Lawlor RT, Scarpa A, Heaphy CM, Wood LD, Wolfgang CL. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. *Ann Surg* 2020;27:566-573
232. Riva G, Villanova M, Eccher A, **Luchini C**, Motta F, Bernasconi R, Barbareschi M. Metastatic malignant melanoma to the gallbladder. Case report and review of the literature. *Pathologica*. 2018 Mar;110(1):68-71.
233. Ascoli V, Murer B, Nottegar A, **Luchini C**, Carella R, Calabrese F, Lunardi F, Cozzi I, Righi L. What's new in mesothelioma. *Pathologica*. 2018 Mar;110(1):12-28.
234. Simbolo M, Vicentini C, Mafficini A, Fassan M, Pedron S, Corbo V, Mastracci L, Rusev B, Pedrazzani C, Landoni L, Grillo F, Cingarlini S, Rindi G, **Luchini C**, Scarpa A, Lawlor RT. Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine. *Virchows Arch*. 2018 Dec;473(6):709-717.

235. Fassan M, Vianello L, Sacchi D, Fanelli GN, Munari G, Scarpa M, Cappellesso R, Loupakis F, Lanza C, Salmaso R, Mescoli C, Valeri N, Agostini M, D'Angelo E, Lonardi S, Pucciarelli S, Veronese N, **Luchini C**, Rugge M. Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. *Cancer Cell Int.* 2018 Sep 6;18:131.
236. Vicentini C, Cantù C, Antonello D, Simbolo M, Mafficini A, **Luchini C**, Rusev B, Porcaro AB, Iacovelli R, Fassan M, Corbo V, Brunelli M, Artibani W, Scarpa A, Lawlor RT. ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. *Pathol Res Pract.* 2018 Oct;214(10):1675-1680.
237. Saraggi D, Galuppini F, Fanelli GN, Remo A, Urso EDL, Bao RQ, Bacchin D, Guzzardo V, **Luchini C**, Braconi C, Farinati F, Rugge M, Fassan M. MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. *Pathol Res Pract.* 2018 Jun;214(6):835-839.
238. Tabbò F, Nottegar A, Guerrera F, Migliore E, **Luchini C**, Maletta F, Veronese N, Montagna L, Gaudio M, Di Giacomo F, Filosso PL, Delsedime L, Ciccone G, Scarpa A, Sapino A, Oliaro A, Ruffini E, Inghirami G, Chilosi M. Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. *Hum Pathol.* 2018 May;75:167-178.
239. Chianchiano P, Pezhouh MK, Kim A, **Luchini C**, Cameron A, Weiss MJ, He J, Voltaggio L, Oshima K, Anders RA, Wood LD. Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations. *Hum Pathol.* 2018 Feb;72:127-134.
240. Saraggi D, Galuppini F, Remo A, Urso EDL, Bacchin D, Salmaso R, Lanza C, Bao RQ, Fanelli GN, Guzzardo V, **Luchini C**, Scarpa M, Farinati F, Fassan M, Rugge M. PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. *Histopathology* 2017; 71(3):470-474.
241. Nicole L, Sanavia T, Veronese N, Cappellesso R, **Luchini C**, Dabrilli P, Fassina A. Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis. *Oncotarget.* 2017; 8:22968-22979.
242. Fassan M, Saraggi D, Balsamo L, Realdon S, Scarpa M, Castoro C, Coati I, Salmaso R, Farinati F, Guzzardo V, Arcidiacono D, Munari G, Gasparini P, Veronese N, **Luchini C**, Valeri N, Rugge M. Early mir-223 upregulation in gastroesophageal carcinogenesis. *Am J Clin Pathol.* 2017;147:301-308.
243. Fassan M, Rusev B, Corbo V, Gasparini P, **Luchini C**, Vicentini C, Mafficini A, Paiella S, Salvia R, Cataldo I, Scarpa A, Huebner K. Fhit down-regulation is an early event in pancreatic carcinogenesis. *Virchows Arch.* 2017; 470:647-653.
244. Yachida S, Wood LD, Suzuki M, Takai E, Totoki Y, Kato M, **Luchini C**, Arai Y, Nakamura H, Hama N, Elzawahry A, Hosoda F, Shirota T, Morimoto N, Hori K, Funazaki J, Tanaka H, Morizane C, Okusaka T, Nara S, Shimada K, Hiraoka N, Taniguchi H, Higuchi R, Oshima M, Okano K, Hirono S, Mizuma M, Arihiro K, Yamamoto M, Unno M, Yamaue H, Weiss MJ, Wolfgang CL, Furukawa T, Nakagama H, Vogelstein B, Kiyono T, Hruban RH, Shibata T. Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. *Cancer Cell.* 2016;29:229-240.
245. Pea A, Yu J, Rezaee N, **Luchini C**, He J, Dal Molin M, Griffin JF, Fedor H, Fesharakizadeh S, Salvia R, Weiss MJ, Bassi C, Cameron JL, Zheng L, Scarpa A, Hruban RH, Lennon AM, Goggins M, Wolfgang CL, Wood LD. Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. *Ann Surg* 2017; 266:133-141.
246. Mafficini A, Amato E, Cataldo I, Rusev BC, Bertinocello L, Corbo V, Simbolo M, **Luchini C**, Fassan M, Cantu C, Salvia R, Marchegiani G, Tortora G, Lawlor RT, Bassi C, Scarpa A. Ampulla of Vater carcinoma: Sequencing analysis identifies TP53 status as a novel independent prognostic factor and potentially actionable ERBB, PI3K, and WNT pathways gene mutations. *Ann Surg.* 2018; 267:149-156.
247. Marchegiani G, Andrianello S, Massignani M, Malleo G, Maggino L, Paiella S, Ferrone CR, **Luchini C**, Scarpa A, Capelli P, Mino-Kenudson M, Lillemoe KD, Bassi C, Castillo CF, Salvia R. Solid pseudopapillary tumors of the pancreas: Specific pathological features predict the likelihood of postoperative recurrence. *J Surg Oncol.* 2016;114:597-601.
248. Mafficini A, Simbolo M, Parisi A, Rusev B, **Luchini C**, Cataldo I, Piazzola E, Sperandio N, Turri G, Franchi M, Tortora G, Bovo C, Lawlor RT, Scarpa A. Brca somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. *Oncotarget.* 2016;7:1076-1083.
249. Kouba EJ, Eble JN, Simper N, Grignon DJ, Wang M, Zhang S, Wang L, Martignoni G, Williamson SR, Brunelli M, **Luchini C**, Calio A, Cheng L. High fidelity of driver chromosomal alterations

- among primary and metastatic renal cell carcinomas: Implications for tumor clonal evolution and treatment. *Mod Pathol*. 2016;29:1347-1357.
250. Veronese N, Zurlo A, Solmi M, **Luchini C**, Trevisan C, Bano G, Manzato E, Sergi G, Rylander R. Magnesium status in alzheimer's disease: A systematic review. *Am J Alzheimers Dis Other Demen*. 2016;31:208-213.
251. Veronese N, Cereda E, Maggi S, **Luchini C**, Solmi M, Smith T, Denking M, Hurley M, Thompson T, Manzato E, Sergi G, Stubbs B. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. *Semin Arthritis Rheum*. 2016;46:160-167.
252. Veronese N, Carraro S, Bano G, Trevisan C, Solmi M, **Luchini C**, Manzato E, Caccialanza R, Sergi G, Nicetto D, Cereda E. Hyperuricemia protects against low bone mineral density, osteoporosis and fractures: A systematic review and meta-analysis. *Eur J Clin Invest*. 2016;46:920-930.
253. Soysal P, Stubbs B, Lucato P, **Luchini C**, Solmi M, Peluso R, Sergi G, Isik AT, Manzato E, Maggi S, Maggio M, Prina AM, Cosco TD, Wu YT, Veronese N. Inflammation and frailty in the elderly: A systematic review and meta-analysis. *Ageing Res Rev* 2016; 31:1-8.
254. Solmi M, Veronese N, Correll CU, Favaro A, Santonastaso P, Caregaro L, Vancampfort D, **Luchini C**, De Hert M, Stubbs B. Bone mineral density, osteoporosis, and fractures among people with eating disorders: A systematic review and meta-analysis. *Acta Psychiatr Scand*. 2016;133:341-351.
255. Di Gennaro F, Pizzol D, Cebola B, Stubbs B, Monno L, Saracino A, **Luchini C**, Solmi M, Segafredo G, Putoto G, Veronese N. Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review. *Tuberculosis (Edinb)*. 2017;103:44-51.
256. Bano G, Trevisan C, Carraro S, Solmi M, **Luchini C**, Stubbs B, Manzato E, Sergi G, Veronese N. Inflammation and sarcopenia: A systematic review and meta-analysis. *Maturitas*. 2017;96:10-15.
257. Stubbs B, Thompson T, Solmi M, Vancampfort D, Sergi G, **Luchini C**, Veronese N. Is pain sensitivity altered in people with alzheimer's disease? A systematic review and meta-analysis of experimental pain research. *Exp Gerontol*. 2016;82:30-38.
258. Lucato P, Trevisan C, Stubbs B, Zanforlini BM, Solmi M, **Luchini C**, Girotti G, Pizzato S, Manzato E, Sergi G, Giannini S, Fusaro M, Veronese N. Nephrolithiasis, bone mineral density, osteoporosis, and fractures: A systematic review and comparative meta-analysis. *Osteoporos Int*. 2016;27:3155-3164.
259. Giuliani S, Ciniselli CM, Leonardi E, Polla E, Decarli N, **Luchini C**, Cantaloni C, Gasperetti F, Cazzolli D, Berlanda G, Bernardi D, Pellegrini M, Triolo R, Ferro A, Verderio P, Barbareschi M. In a cohort of breast cancer screened patients the proportion of her2 positive cases is lower than that earlier reported and pathological characteristics differ between her2 3+ and her2 2+/her2 amplified cases. *Virchows Arch*. 2016;469:45-50.
260. Calio A, Eble JN, Hes O, Martignoni G, Harari SE, Williamson SR, Brunelli M, Osunkoya AO, Wang L, Comperat E, Lopez-Beltran A, Wang M, Zhang S, Curless KL, Post KM, Chang HY, **Luchini C**, Baldrige LA, MacLennan GT, Montironi R, Grignon DJ, Cheng L. Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. *Oncotarget*. 2016; 8:54096-54105.
261. Amato E, Barbi S, Fassan M, **Luchini C**, Vicentini C, Brunelli M, Malleo G, Scarpa A, Malpeli G. RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: Correlation of expression, chromosomal status and epigenetic changes. *BMC Cancer*. 2016;16:11.
262. De Marchi G, Cerruto MA, D'Elia C, Brunelli M, Otte O, Minja A, **Luchini C**, Novella G, Cavalleri S, Martignoni G, Artibani W. Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder. *Mol Clin Oncol*. 2014;2:575-580.
263. Massari F, Ciccarese C, Modena A, Maines F, Segala D, **Luchini C**, Marcolini L, Cavicchioli F, Cavalleri S, Bria E, Brunelli M, Martignoni G, Artibani W, Tortora G. Adenocarcinoma of the paraurethral glands: A case report. *Histol Histopathol*. 2014;29:1295-1303.
264. Fassan M, Simbolo M, Bria E, Mafficini A, Pilotto S, Capelli P, Bencivenga M, Pecori S, **Luchini C**, Neves D, Turri G, Vicentini C, Montagna L, Tomezzoli A, Tortora G, Chilosi M, De Manzoni G, Scarpa A. High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. *Gastric Cancer*. 2014;17:442-449.

Ulteriori lavori in cui il Prof. Luchini ha collaborato in qualità di esperto di revisioni sistematiche e meta-analisi

265. **Luchini C**, Veronese N, Nottegar A, Shin JI, Gentile G, Granzio U, Soysal P, Alexinschi O, Smith L, Solmi M. Assessing the quality of studies in meta-research: Review/guidelines on the most important quality assessment tools. *Pharm Stat.* 2021 Jan;20(1):185-195.
266. **Luchini C**, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. *World J Meta-Anal* 2017;5(4):80-84.
267. Veronese N, Facchini S, Stubbs B, **Luchini C**, Solmi M, Manzato E, Sergi G, Maggi S, Cosco T, Fontana L. Weight loss is associated with improvements in cognitive function among overweight and obese people: A systematic review and meta-analysis. *Neurosci Biobehav Rev.* 2017;72:87-94.
268. Veronese N, Cereda E, Stubbs B, Solmi M, **Luchini C**, Manzato E, Sergi G, Manu P, Harris T, Fontana L, Strandberg T, Amieva H, Dumurgier J, Elbaz A, Tzourio C, Eicholzer M, Rohrmann S, Moretti C, D'Ascenzo F, Quadri G, Polidoro A, Lourenco RA, Moreira VG, Sanchis J, Scotti V, Maggi S, Correll CU. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. *Ageing Res Rev.* 2017;35:63-73.
269. Veronese N, Watutantrige-Fernando S, **Luchini C**, Solmi M, Sartore G, Sergi G, Manzato E, Barbagallo M, Maggi S, Stubbs B. Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: A systematic review and meta-analysis of double-blind randomized controlled trials. *Eur J Clin Nutr.* 2016;70:1354-1359.
270. Veronese N, Stubbs B, Noale M, Solmi M, **Luchini C**, Smith TO, Cooper C, Guglielmi G, Reginster JY, Rizzoli R, Maggi S. Adherence to a mediterranean diet is associated with lower prevalence of osteoarthritis: Data from the osteoarthritis initiative. *Clin Nutr.* 2016.
271. Veronese N, Stubbs B, Noale M, Solmi M, **Luchini C**, Maggi S. Adherence to the mediterranean diet is associated with better quality of life: Data from the osteoarthritis initiative. *Am J Clin Nutr.* 2016;104:1403-1409.
272. Ometto F, Stubbs B, Annweiler C, Duval GT, Jang W, Kim HT, McCarroll K, Cunningham C, Soysal P, Isik AT, **Luchini C**, Solmi M, Sergi G, Manzato E, Veronese N. Hypovitaminosis D and orthostatic hypotension: a systematic review and meta-analysis. *J Hypertens.* 2016 Jun;34(6):1036-43.
273. Veronese N, Solmi M, **Luchini C**, Lu RB, Stubbs B, Zaninotto L, Correll CU. Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. *J Affect Disord.* 2016;197:268-280.
274. Soysal P, Isik AT, Stubbs B, Solmi M, Volpe M, **Luchini C**, D'Onofrio G, Pilotto A, Manzato E, Sergi G, Schofield P, Veronese N. Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: A systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry.* 2016;87:1368-1374.
275. Solmi M, Veronese N, Sergi G, **Luchini C**, Favaro A, Santonastaso P, Vancampfort D, Correll CU, Ussher M, Thapa-Chhetri N, Fornaro M, Stubbs B. The association between smoking prevalence and eating disorders: A systematic review and meta-analysis. *Addiction.* 2016;111:1914-1922.
276. Solmi M, Veronese N, **Luchini C**, Manzato E, Sergi G, Favaro A, Santonastaso P, Correll CU. Oxidative stress and antioxidant levels in patients with anorexia nervosa after oral re-alimentation: A systematic review and exploratory meta-analysis. *Eur Eat Disord Rev.* 2016;24:101-105.

Ulteriori lavori in cui il Prof. Luchini ha collaborato in qualità di membro di consorzi scientifici:

Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium

277. Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S; MC3 Working Group; PCAWG novel somatic mutation calling methods working group; Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L; PCAWG Consortium. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. *Nat Commun.* 2020 Sep 21;11(1):4748. doi: 10.1038/s41467-020-18151-y. Erratum in: *Nat Commun.* 2020 Nov 30;11(1):6232.

278. Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N; PCAWG Tumour Subtypes and Clinical Translation; Boutros PC; PCAWG Consortium. Sex differences in oncogenic mutational processes. *Nat Commun*. 2020 Aug 28;11(1):4330.
279. PCAWG Transcriptome Core Group; Calabrese C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraiishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, Perry MD, Xiang Q, Zhang F, Zhang J, Bailey P, Erkek S, Hoadley KA, Hou Y, Huska MR, Kilpinen H, Korbel JO, Marin MG, Markowski J, Nandi T, Pan-Hammarström Q, Pedamallu CS, Siebert R, Stark SG, Su H, Tan P, Waszak SM, Yung C, Zhu S, Awadalla P, Creighton CJ, Meyerson M, Ouellette BFF, Wu K, Yang H; PCAWG Transcriptome Working Group; Brazma A, Brooks AN, Göke J, Rättsch G, Schwarz RF, Stegle O, Zhang Z; PCAWG Consortium. Genomic basis for RNA alterations in cancer. *Nature*. 2020 Feb;578(7793):129-136. doi: 10.1038/s41586-020-1970-0. Epub 2020 Feb 5. Erratum in: *Nature*. 2023 Feb;614(7948):E37.
280. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstrom EN, Islam SMA, Lopez-Bigas N, Klimczak LJ, McPherson JR, Morganella S, Sabarinathan R, Wheeler DA, Mustonen V; PCAWG Mutational Signatures Working Group; Getz G, Rozen SG, Stratton MR; PCAWG Consortium. The repertoire of mutational signatures in human cancer. *Nature*. 2020 Feb;578(7793):94-101. doi: 10.1038/s41586-020-1943-3. Epub 2020 Feb 5. Erratum in: *Nature*. 2023 Feb;614(7948):E41.
281. Rheinbay E, Nielsen MM, Abascal F, Wala JA, Shapira O, Tiao G, Hornshøj H, Hess JM, Juul RI, Lin Z, Feuerbach L, Sabarinathan R, Madsen T, Kim J, Mularoni L, Shuai S, Lanzós A, Herrmann C, Maruvka YE, Shen C, Amin SB, Bandopadhyay P, Bertl J, Boroevich KA, Busanovich J, Carlevaro-Fita J, Chakravarty D, Chan CWY, Craft D, Dhingra P, Diamanti K, Fonseca NA, Gonzalez-Perez A, Guo Q, Hamilton MP, Haradhvala NJ, Hong C, Isaev K, Johnson TA, Juul M, Kahles A, Kahraman A, Kim Y, Komorowski J, Kumar K, Kumar S, Lee D, Lehmann KV, Li Y, Liu EM, Lochovsky L, Park K, Pich O, Roberts ND, Saksena G, Schumacher SE, Sidiropoulos N, Sieverling L, Sinnott-Armstrong N, Stewart C, Tamborero D, Tubio JMC, Umer HM, Uusküla-Reimand L, Wadelius C, Wadi L, Yao X, Zhang CZ, Zhang J, Haber JE, Hobolth A, Imielinski M, Kellis M, Lawrence MS, von Mering C, Nakagawa H, Raphael BJ, Rubin MA, Sander C, Stein LD, Stuart JM, Tsunoda T, Wheeler DA, Johnson R, Reimand J, Gerstein M, Khurana E, Campbell PJ, López-Bigas N; PCAWG Drivers and Functional Interpretation Working Group; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukhim R, Martincorena I, Pedersen JS, Getz G; PCAWG Consortium. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. *Nature*. 2020 Feb;578(7793):102-111. doi: 10.1038/s41586-020-1965-x. Epub 2020 Feb 5. Erratum in: *Nature*. 2023 Feb;614(7948):E40.
282. Gerstung M, Jolly C, Leshchiner I, D'Entro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, Haase K, Jerman L, Sengupta S, Macintyre G, Malikić S, Donmez N, Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X, Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G, Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Markowitz F, Mustonen V, Yuan K, Wang W, Morris QD; PCAWG Evolution & Heterogeneity Working Group; Spellman PT, Wedge DC, Van Loo P; PCAWG Consortium. The evolutionary history of 2,658 cancers. *Nature*. 2020 Feb;578(7793):122-128. doi: 10.1038/s41586-019-1907-7. Epub 2020 Feb 6. Erratum in: *Nature*. 2023 Feb;614(7948):E42.
283. Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, Khurana E, Waszak S, Korbel JO, Haber JE, Imielinski M; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukhim R, Campbell PJ; PCAWG Consortium. Patterns of somatic structural variation in human cancer genomes. *Nature*. 2020 Feb;578(7793):112-121. doi: 10.1038/s41586-019-1913-9. Epub 2020 Feb 5. Erratum in: *Nature*. 2023 Feb;614(7948):E38.

284. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. *Nature*. 2020 Feb;578(7793):82-93. doi: 10.1038/s41586-020-1969-6. Epub 2020 Feb 5. Erratum in: *Nature*. 2023 Feb;614(7948):E39.
285. Cortés-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS; PCAWG Structural Variation Working Group; Park PJ; PCAWG Consortium. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. *Nat Genet*. 2020 Mar;52(3):331-341. doi: 10.1038/s41588-019-0576-7. Epub 2020 Feb 5. Erratum in: *Nat Genet*. 2023 May;55(5):893. doi: 10.1038/s41588-020-0634-1. Erratum in: *Nat Genet*. 2023 Jun;55(6):1076.
286. Zapatka M, Borozan I, Brewer DS, Iskar M, Grundhoff A, Alawi M, Desai N, Sülthmann H, Moch H; PCAWG Pathogens; Cooper CS, Eils R, Ferretti V, Lichter P; PCAWG Consortium. The landscape of viral associations in human cancers. *Nat Genet*. 2020 Mar;52(3):320-330. doi: 10.1038/s41588-019-0558-9. Epub 2020 Feb 5. Erratum in: *Nat Genet*. 2023 Jun;55(6):1077.
287. Akdemir KC, Le VT, Chandran S, Li Y, Verhaak RG, Beroukhim R, Campbell PJ, Chin L, Dixon JR, Futreal PA; PCAWG Structural Variation Working Group; PCAWG Consortium. Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. *Nat Genet*. 2020 Mar;52(3):294-305. doi: 10.1038/s41588-019-0564-y. Epub 2020 Feb 5. Erratum in: *Nat Genet*. 2023 Jun;55(6):1079.
288. Rodriguez-Martin B, Alvarez EG, Baez-Ortega A, Zamora J, Supek F, Demeulemeester J, Santamarina M, Ju YS, Temes J, Garcia-Souto D, Detering H, Li Y, Rodriguez-Castro J, Dueso-Barroso A, Bruzos AL, Dentro SC, Blanco MG, Contino G, Ardeljan D, Tojo M, Roberts ND, Zumalave S, Edwards PA, Weischenfeldt J, Puiggròs M, Chong Z, Chen K, Lee EA, Wala JA, Raine KM, Butler A, Waszak SM, Navarro FCP, Schumacher SE, Monlong J, Maura F, Bolli N, Bourque G, Gerstein M, Park PJ, Wedge DC, Beroukhim R, Torrents D, Korbel JO, Martincorena I, Fitzgerald RC, Van Loo P, Kazazian HH, Burns KH; PCAWG Structural Variation Working Group; Campbell PJ, Tubio JMC; PCAWG Consortium. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. *Nat Genet*. 2020 Mar;52(3):306-319. doi: 10.1038/s41588-019-0562-0. Epub 2020 Feb 5. Erratum in: *Nat Genet*. 2023 Jun;55(6):1080.
289. Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, Yang Y, Martincorena I, Creighton CJ, Weinstein JN, Xu Y, Han L, Kim HL, Nakagawa H, Park K, Campbell PJ, Liang H; PCAWG Consortium. Comprehensive molecular characterization of mitochondrial genomes in human cancers. *Nat Genet*. 2020 Mar;52(3):342-352. doi: 10.1038/s41588-019-0557-x. Epub 2020 Feb 5. Erratum in: *Nat Genet*. 2023 May;55(5):893. doi: 10.1038/s41588-020-0587-4. Erratum in: *Nat Genet*. 2023 May;55(5):892. doi: 10.1038/s41588-020-0629-y. Erratum in: *Nat Genet*. 2023 Jun;55(6):1078.
290. Carlevaro-Fita J, Lanzós A, Feuerbach L, Hong C, Mas-Ponte D, Pedersen JS; PCAWG Drivers and Functional Interpretation Group; Johnson R; PCAWG Consortium. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. *Commun Biol*. 2020 Feb 5;3(1):56. doi: 10.1038/s42003-019-0741-7. Erratum in: *Commun Biol*. 2022 Dec 8;5(1):1347.
291. Yakneen S, Waszak SM; PCAWG Technical Working Group; Gertz M, Korbel JO; PCAWG Consortium. Butler enables rapid cloud-based analysis of thousands of human genomes. *Nat Biotechnol*. 2020 Mar;38(3):288-292. doi: 10.1038/s41587-019-0360-3. Epub 2020 Feb 5. Erratum in: *Nat Biotechnol*. 2023 Apr;41(4):578. doi: 10.1038/s41587-020-0448-9. Erratum in: *Nat Biotechnol*. 2023 Apr;41(4):577.
292. Reyna MA, Haan D, Paczkowska M, Verbeke LPC, Vazquez M, Kahraman A, Pulido-Tamayo S, Barenboim J, Wadi L, Dhingra P, Shrestha R, Getz G, Lawrence MS, Pedersen JS, Rubin MA, Wheeler DA, Brunak S, Izarzugaza JMG, Khurana E, Marchal K, von Mering C, Sahinalp SC, Valencia A; PCAWG Drivers and Functional Interpretation Working Group; Reimand J, Stuart JM, Raphael BJ; PCAWG Consortium. Pathway and network analysis of more than 2500 whole cancer

- genomes. *Nat Commun.* 2020 Feb 5;11(1):729. doi: 10.1038/s41467-020-14367-0. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7566.
293. Jiao W, Atwal G, Polak P, Karlic R, Cuppen E; PCAWG Tumor Subtypes and Clinical Translation Working Group; Danyi A, de Ridder J, van Herpen C, Lolkema MP, Steeghs N, Getz G, Morris QD, Stein LD; PCAWG Consortium. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. *Nat Commun.* 2020 Feb 5;11(1):728. doi: 10.1038/s41467-019-13825-8. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7573.
294. Paczkowska M, Barenboim J, Sintupisut N, Fox NS, Zhu H, Abd-Rabbo D, Mee MW, Boutros PC; PCAWG Drivers and Functional Interpretation Working Group; Reimand J; PCAWG Consortium. Integrative pathway enrichment analysis of multivariate omics data. *Nat Commun.* 2020 Feb 5;11(1):735. doi: 10.1038/s41467-019-13983-9. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7570.
295. Cmero M, Yuan K, Ong CS, Schröder J; PCAWG Evolution and Heterogeneity Working Group; Corcoran NM, Papenfuss T, Hovens CM, Markowitz F, Macintyre G; PCAWG Consortium. Inferring structural variant cancer cell fraction. *Nat Commun.* 2020 Feb 5;11(1):730. doi: 10.1038/s41467-020-14351-8. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7568.
296. Rubanova Y, Shi R, Harrigan CF, Li R, Wintersinger J, Sahin N, Deshwar AG; PCAWG Evolution and Heterogeneity Working Group; Morris QD; PCAWG Consortium. Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. *Nat Commun.* 2020 Feb 5;11(1):731. doi: 10.1038/s41467-020-14352-7. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7567.
297. Zhang Y, Chen F, Fonseca NA, He Y, Fujita M, Nakagawa H, Zhang Z, Brazma A; PCAWG Transcriptome Working Group; PCAWG Structural Variation Working Group; Creighton CJ; PCAWG Consortium. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. *Nat Commun.* 2020 Feb 5;11(1):736. doi: 10.1038/s41467-019-13885-w. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7572.
298. Bhandari V, Li CH, Bristow RG, Boutros PC; PCAWG Consortium. Divergent mutational processes distinguish hypoxic and normoxic tumours. *Nat Commun.* 2020 Feb 5;11(1):737. doi: 10.1038/s41467-019-14052-x. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7569.
299. Shuai S; PCAWG Drivers and Functional Interpretation Working Group; Gallinger S, Stein LD; PCAWG Consortium. Combined burden and functional impact tests for cancer driver discovery using DriverPower. *Nat Commun.* 2020 Feb 5;11(1):734. doi: 10.1038/s41467-019-13929-1. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7571.
300. Sieverling L, Hong C, Koser SD, Ginsbach P, Kleinheinz K, Hutter B, Braun DM, Cortés-Ciriano I, Xi R, Kabbe R, Park PJ, Eils R, Schlesner M; PCAWG-Structural Variation Working Group; Brors B, Rippe K, Jones DTW, Feuerbach L; PCAWG Consortium. Genomic footprints of activated telomere maintenance mechanisms in cancer. *Nat Commun.* 2020 Feb 5;11(1):733. doi: 10.1038/s41467-019-13824-9. Erratum in: *Nat Commun.* 2022 Dec 8;13(1):7574.

Pancreatobiliary and Hepatic Artificial Intelligence Research (PHAIR) Consortium

301. Bereska JI, Zeeuw M, Wagenaar L, Jenssen HB, Wesdorp NJ, van der Meulen D, Bereska LF, Gavves E, Janssen BV, Besselink MG, Marquering HA, van Waesberghe JTM, Aghayan DL, Pelanis E, van den Bergh J, Nota IIM, Moos S, Kemmerich G, Syversveen T, Kolrud FK, Huiskens J, Swijnenburg RJ, Punt CJA, Stoker J, Edwin B, Fretland ÅA, Kazemier G, Verpalen IM; Pancreatobiliary and Hepatic Artificial Intelligence Research (PHAIR) consortium; Dutch Colorectal Cancer Group Liver Expert Panel. Development and external evaluation of a self-learning auto-segmentation model for Colorectal Cancer Liver Metastases Assessment (COALA). *Insights Imaging.* 2024 Nov 22;15(1):279.

European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS)

302. Bruna CL, van Hilst J, Korrel M, Jones LR, Balzano G, Björnsson B, Boggi U, Bratlie SO, Busch OR, Butturini G, Capretti G, Casadei R, Dokmak S, Edwin B, Esposito A, Falconi M, Ferrari G, Hackert T, Kazemier G, Koerkamp BG, de Kleine RH, Keck T, Kleive DB, Kokkola A, Kooby D, Lips DJ, Luyer MDP, Guerra M, Marudanayagam R, Menon K, Molenaar IQ, de Pastena M, Pecorelli N, Primrose JN, Ricci C, Saint Marc O, Salvia R, Sandström P, Tomazic A, Wellner UF, Yip VS, Zerbi A, Ali M, Dijkgraaf MGW, Besselink MG, Abu Hilal M; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. *JAMA Surg.* 2025 Dec 1;160(12):1299-1307.
303. Korrel M, Jones LR, van Hilst J, Balzano G, Björnsson B, Boggi U, Bratlie SO, Busch OR, Butturini G, Capretti G, Casadei R, Edwin B, Emmen AMLH, Esposito A, Falconi M, Groot Koerkamp B, Keck T, de Kleine RHJ, Kleive DB, Kokkola A, Lips DJ, Lof S, Luyer MDP, Manzoni A, Marudanayagam R, de Pastena M, Pecorelli N, Primrose JN, Ricci C, Salvia R, Sandström P, Vissers FLIM, Wellner UF, Zerbi A, Dijkgraaf MGW, Besselink MG, Abu Hilal M; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. *Lancet Reg Health Eur.* 2023 Jul 6;31:100673.

Ulteriori prodotti scientifici (es.: corrigendum, correzioni pubblicate)

304. Grillo F, Angerilli V, Parente P, Vanoli A, Luchini C, Sciallero S, Puccini A, Bergamo F, Lonardi S, Valeri N, Mastracci L, Fassan M. Correction to: Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting. *Virchows Arch.* 2024 Nov;485(5):955. doi: 10.1007/s00428-024-03733-8. Erratum for: *Virchows Arch.* 2024 Jul;485(1):131-135.
305. Yakneen S, Waszak SM; PCAWG Technical Working Group; Gertz M, Korbel JO; PCAWG Consortium. Author Correction: Butler enables rapid cloud-based analysis of thousands of human genomes. *Nat Biotechnol.* 2023 Apr;41(4):577. doi: 10.1038/s41587-022-01554-1. Erratum for: *Nat Biotechnol.* 2020 Mar;38(3):288-292.
306. Rodriguez-Martin B, Alvarez EG, Baez-Ortega A, Zamora J, Supek F, Demeulemeester J, Santamarina M, Ju YS, Temes J, Garcia-Souto D, Detering H, Li Y, Rodriguez-Castro J, Dueso-Barroso A, Bruzos AL, Dentro SC, Blanco MG, Contino G, Ardeljan D, Tojo M, Roberts ND, Zumalave S, Edwards PA, Weischenfeldt J, Puiggròs M, Chong Z, Chen K, Lee EA, Wala JA, Raine KM, Butler A, Waszak SM, Navarro FCP, Schumacher SE, Monlong J, Maura F, Bolli N, Bourque G, Gerstein M, Park PJ, Wedge DC, Beroukhir R, Torrents D, Korbel JO, Martincorena I, Fitzgerald RC, Van Loo P, Kazazian HH, Burns KH; PCAWG Structural Variation Working Group; Campbell PJ, Tubio JMC; PCAWG Consortium. Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. *Nat Genet.* 2023 Jun;55(6):1080. doi: 10.1038/s41588-023-01319-9. Erratum for: *Nat Genet.* 2020 Mar;52(3):306-319.
307. Akdemir KC, Le VT, Chandran S, Li Y, Verhaak RG, Beroukhir R, Campbell PJ, Chin L, Dixon JR, Futreal PA; PCAWG Structural Variation Working Group; PCAWG Consortium. Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. *Nat Genet.* 2023 Jun;55(6):1079. doi: 10.1038/s41588-023-01318-w. Erratum for: *Nat Genet.* 2020 Mar;52(3):294-305.
308. Zapatka M, Borozan I, Brewer DS, Iskar M, Grundhoff A, Alawi M, Desai N, Sülthmann H, Moch H; PCAWG Pathogens; Cooper CS, Eils R, Ferretti V, Lichter P; PCAWG Consortium. Author Correction: The landscape of viral associations in human cancers. *Nat Genet.* 2023 Jun;55(6):1077. doi: 10.1038/s41588-023-01316-y. Erratum for: *Nat Genet.* 2020 Mar;52(3):320-330.

309. Cortés-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS; PCAWG Structural Variation Working Group; Park PJ; PCAWG Consortium. Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. *Nat Genet.* 2023 Jun;55(6):1076. doi: 10.1038/s41588-023-01315-z. Erratum for: *Nat Genet.* 2020 Mar;52(3):331-341.
310. Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, Yang Y, Martincorena I, Creighton CJ, Weinstein JN, Xu Y, Han L, Kim HL, Nakagawa H, Park K, Campbell PJ, Liang H; PCAWG Consortium. Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers. *Nat Genet.* 2023 Jun;55(6):1078. doi: 10.1038/s41588-023-01317-x. Erratum for: *Nat Genet.* 2020 Mar;52(3):342-352.
311. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstrom EN, Islam SMA, Lopez-Bigas N, Klimczak LJ, McPherson JR, Morganello S, Sabarinathan R, Wheeler DA, Mustonen V; PCAWG Mutational Signatures Working Group; Getz G, Rozen SG, Stratton MR; PCAWG Consortium. Author Correction: The repertoire of mutational signatures in human cancer. *Nature.* 2023 Feb;614(7948):E41. doi: 10.1038/s41586-022-05600-5. Erratum for: *Nature.* 2020 Feb;578(7793):94-101.
312. Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, Khurana E, Waszak S, Korbel JO, Haber JE, Imielinski M; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukhim R, Campbell PJ; PCAWG Consortium. Author Correction: Patterns of somatic structural variation in human cancer genomes. *Nature.* 2023 Feb;614(7948):E38. doi: 10.1038/s41586-022-05597-x. Erratum for: *Nature.* 2020 Feb;578(7793):112-121.
313. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Author Correction: Pan-cancer analysis of whole genomes. *Nature.* 2023 Feb;614(7948):E39. doi: 10.1038/s41586-022-05598-w. Erratum for: *Nature.* 2020 Feb;578(7793):82-93.
314. Gerstung M, Jolly C, Leshchiner I, Dentre SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, Haase K, Jerman L, Sengupta S, Macintyre G, Malikic S, Donmez N, Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X, Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G, Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Markowitz F, Mustonen V, Yuan K, Wang W, Morris QD; PCAWG Evolution & Heterogeneity Working Group; Spellman PT, Wedge DC, Van Loo P; PCAWG Consortium. Author Correction: The evolutionary history of 2,658 cancers. *Nature.* 2023 Feb;614(7948):E42. doi: 10.1038/s41586-022-05601-4. Erratum for: *Nature.* 2020 Feb;578(7793):122-128.
315. Rheinbay E, Nielsen MM, Abascal F, Wala JA, Shapira O, Tiao G, Hornshøj H, Hess JM, Juul RI, Lin Z, Feuerbach L, Sabarinathan R, Madsen T, Kim J, Mularoni L, Shuai S, Lanzós A, Herrmann C, Maruvka YE, Shen C, Amin SB, Bandopadhyay P, Bertl J, Boroevich KA, Busanovich J, Carlevaro-Fita J, Chakravarty D, Chan CWY, Craft D, Dhingra P, Diamanti K, Fonseca NA, Gonzalez-Perez A, Guo Q, Hamilton MP, Haradhvala NJ, Hong C, Isaev K, Johnson TA, Juul M, Kahles A, Kahraman A, Kim Y, Komorowski J, Kumar K, Kumar S, Lee D, Lehmann KV, Li Y, Liu EM, Lochovsky L, Park K, Pich O, Roberts ND, Saksena G, Schumacher SE, Sidiropoulos N, Sieverling L, Sinnott-Armstrong N, Stewart C, Tamborero D, Tubio JMC, Umer HM, Uusküla-Reimand L, Wadelius C, Wadi L, Yao X, Zhang CZ, Zhang J, Haber JE, Hobolth A, Imielinski M, Kellis M, Lawrence MS, von Mering C, Nakagawa H, Raphael BJ, Rubin MA, Sander C, Stein LD, Stuart JM, Tsunoda T, Wheeler DA, Johnson R, Reimand J, Gerstein M, Khurana E, Campbell PJ, López-Bigas N; PCAWG Drivers and Functional Interpretation Working Group; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukhim R, Martincorena I, Pedersen JS, Getz G; PCAWG Consortium. Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. *Nature.* 2023 Feb;614(7948):E40. doi: 10.1038/s41586-022-05599-9. Erratum for: *Nature.* 2020 Feb;578(7793):102-111.

316. PCAWG Transcriptome Core Group; Calabrese C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, Perry MD, Xiang Q, Zhang F, Zhang J, Bailey P, Erkek S, Hoadley KA, Hou Y, Huska MR, Kilpinen H, Korbel JO, Marin MG, Markowski J, Nandi T, Pan-Hammarström Q, Pedomallu CS, Siebert R, Stark SG, Su H, Tan P, Waszak SM, Yung C, Zhu S, Awadalla P, Creighton CJ, Meyerson M, Ouellette BFF, Wu K, Yang H; PCAWG Transcriptome Working Group; Brazma A, Brooks AN, Göke J, Rättsch G, Schwarz RF, Stegle O, Zhang Z; PCAWG Consortium. Author Correction: Genomic basis for RNA alterations in cancer. *Nature*. 2023 Feb;614(7948):E37. doi: 10.1038/s41586-022-05596-y. Erratum for: *Nature*. 2020 Feb;578(7793):129-136.
317. Carlevaro-Fita J, Lanzós A, Feuerbach L, Hong C, Mas-Ponte D, Pedersen JS; PCAWG Drivers and Functional Interpretation Group; Johnson R; PCAWG Consortium. Author Correction: Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. *Commun Biol*. 2022 Dec 8;5(1):1347. doi: 10.1038/s42003-022-03769-z. Erratum for: *Commun Biol*. 2020 Feb 5;3(1):56.
318. Rubanova Y, Shi R, Harrigan CF, Li R, Wintersinger J, Sahin N, Deshwar AG; PCAWG Evolution and Heterogeneity Working Group; Morris QD; PCAWG Consortium. Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. *Nat Commun*. 2022 Dec 8;13(1):7567. doi: 10.1038/s41467-022-32336-7. Erratum for: *Nat Commun*. 2020 Feb 5;11(1):731.
319. Sieverling L, Hong C, Koser SD, Ginsbach P, Kleinheinz K, Hutter B, Braun DM, Cortés-Ciriano I, Xi R, Kabbe R, Park PJ, Eils R, Schlesner M; PCAWG-Structural Variation Working Group; Brors B, Rippe K, Jones DTW, Feuerbach L; PCAWG Consortium. Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer. *Nat Commun*. 2022 Dec 8;13(1):7574. doi: 10.1038/s41467-022-32328-7. Erratum for: *Nat Commun*. 2020 Feb 5;11(1):733.
320. Shuai S; PCAWG Drivers and Functional Interpretation Working Group; Gallinger S, Stein LD; PCAWG Consortium. Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower. *Nat Commun*. 2022 Dec 8;13(1):7571. doi: 10.1038/s41467-022-32343-8. Erratum for: *Nat Commun*. 2020 Feb 5;11(1):734.
321. Cmero M, Yuan K, Ong CS, Schröder J; PCAWG Evolution and Heterogeneity Working Group; Corcoran NM, Papenfuss T, Hovens CM, Markowitz F, Macintyre G; PCAWG Consortium. Author Correction: Inferring structural variant cancer cell fraction. *Nat Commun*. 2022 Dec 8;13(1):7568. doi: 10.1038/s41467-022-32338-5. Erratum for: *Nat Commun*. 2020 Feb 5;11(1):730.
322. Jiao W, Atwal G, Polak P, Karlic R, Cuppen E; PCAWG Tumor Subtypes and Clinical Translation Working Group; Danyi A, de Ridder J, van Herpen C, Lolkema MP, Steeghs N, Getz G, Morris QD, Stein LD; PCAWG Consortium. Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. *Nat Commun*. 2022 Dec 8;13(1):7573. doi: 10.1038/s41467-022-32329-6. Erratum for: *Nat Commun*. 2020 Feb 5;11(1):728.
323. Paczkowska M, Barenboim J, Sintupisut N, Fox NS, Zhu H, Abd-Rabbo D, Mee MW, Boutros PC; PCAWG Drivers and Functional Interpretation Working Group; Reimand J; PCAWG Consortium. Author Correction: Integrative pathway enrichment analysis of multivariate omics data. *Nat Commun*. 2022 Dec 8;13(1):7570. doi: 10.1038/s41467-022-32342-9. Erratum for: *Nat Commun*. 2020 Feb 5;11(1):735.
324. Zhang Y, Chen F, Fonseca NA, He Y, Fujita M, Nakagawa H, Zhang Z, Brazma A; PCAWG Transcriptome Working Group; PCAWG Structural Variation Working Group; Creighton CJ; PCAWG Consortium. Author Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. *Nat Commun*. 2022 Dec 8;13(1):7572. doi: 10.1038/s41467-022-32333-w. Erratum for: *Nat Commun*. 2020 Feb 5;11(1):736.

325. Bhandari V, Li CH, Bristow RG, Boutros PC; PCAWG Consortium. Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours. *Nat Commun.* 2022 Dec 8;13(1):7569. doi: 10.1038/s41467-022-32339-4. Erratum for: *Nat Commun.* 2020 Feb 5;11(1):737.
326. Reyna MA, Haan D, Paczkowska M, Verbeke LPC, Vazquez M, Kahraman A, Pulido-Tamayo S, Barenboim J, Wadi L, Dhingra P, Shrestha R, Getz G, Lawrence MS, Pedersen JS, Rubin MA, Wheeler DA, Brunak S, Izarzugaza JMG, Khurana E, Marchal K, von Mering C, Sahinalp SC, Valencia A; PCAWG Drivers and Functional Interpretation Working Group; Reimand J, Stuart JM, Raphael BJ; PCAWG Consortium. Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes. *Nat Commun.* 2022 Dec 8;13(1):7566. doi: 10.1038/s41467-022-32334-9. Erratum for: *Nat Commun.* 2020 Feb 5;11(1):729.
327. Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S; MC3 Working Group; PCAWG novel somatic mutation calling methods working group; Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L; PCAWG Consortium. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. *Nat Commun.* 2020 Nov 30;11(1):6232. doi: 10.1038/s41467-020-20128-w. Erratum for: *Nat Commun.* 2020 Sep 21;11(1):4748.
328. Fassan M, Vianello L, Sacchi D, Fanelli GN, Munari G, Scarpa M, Cappellesso R, Loupakis F, Lanza C, Salmaso R, Mescoli C, Valeri N, Agostini M, D'Angelo E, Lonardi S, Pucciarelli S, Veronese N, Luchini C, Rugge M. Correction to: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. *Cancer Cell Int.* 2019 Sep 24;19:244. doi: 10.1186/s12935-019-0966-z. Erratum for: *Cancer Cell Int.* 2018 Sep 06;18:131. doi: 10.1186/s12935-018-0634-8. PMID: 31572061; PMCID: PMC6757372.
329. Soysal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R, Sergi G, Isik AT, Manzato E, Maggi S, Maggio M, Prina AM, Cosco TD, Wu YT, Veronese N. Corrigendum to "Inflammation and frailty in the elderly: A systematic review and meta-analysis" [*Ageing Res Rev.* 31 (2016) 1-8]. *Ageing Res Rev.* 2017 May;35:364-365. doi: 10.1016/j.arr.2016.12.007. Epub 2017 Jan 13. Erratum for: *Ageing Res Rev.* 2016 Nov;31:1-8. doi: 10.1016/j.arr.2016.08.006. PMID: 28089523.

CAPITOLI DI LIBRI

Capitoli di libri WHO Classification of Tumours (bluebook)

Coautore in 2 capitoli in WHO Classification of Tumours, 5th edition, Genetic Tumour Syndromes (In Press e online beta version):

- 1) Peutz-Jeghers syndromes (STK11)
- 2) PALB2-related cancer predisposition syndrome (PALB2)

Coautore in 4 capitoli in WHO Classification of Tumours, 6th edition, Digestive System Tumours [In Press]:

- 3) Pancreatic ductal adenocarcinoma
- 4) Intraductal mucocystic papillary neoplasm of the pancreas (responsible author)
- 5) Intraductal tubulopapillary neoplasm of the pancreas (responsible author)
- 6) Hereditary and familial pancreatic cancer (BRCA1, BRCA2, PALB2, RAD51C, RAD51D, FANCC & others)

Capitoli di libri (tiratura internazionale)

- 7) **Luchini C**, Simbolo M, Scarpa A. Pathology of Biliary Tract Cancer. In: The IASGO Textbook of Multi-disciplinary Management of Hepato-Pancreato-Biliary Diseases, Makuuchi M, Kokudo N, Popescu I, Belghiti J, Han H-S, Takaori K, Duda D (ed.), Springer Nature Singapore 2022.
- 8) Mafficini A, Corbo V, Barbi S, **Luchini C**, Simbolo M, Scarpa A. Molecular Biology of Neuroendocrine Tumors. In: Neuroendocrine Neoplasia Management. Beretta G, Berruti A, Bombardieri E, Fazio N, Goletti O (ed.). Springer Nature 2021.
- 9) **Luchini C**, Lever V, Nottegar A. Cystic Fibrosis. In: Encyclopedia of Pathology, H. V. Krieken (ed.), Springer Nature Switzerland AG 2020.
- 10) **Luchini C**, Fiadone G, Lever V. Multiple Endocrine Neoplasia, Type 1 (MEN1). In: Encyclopedia of Pathology, H. V. Krieken (ed.), Springer Nature Switzerland AG 2020.
- 11) **Luchini C**, Lever V. Von Hippel-Lindau Disease. In: Encyclopedia of Pathology, H. V. Krieken (ed.), Springer Nature Switzerland AG 2020.
- 12) Paolino G, Lever V, **Luchini C**. Hereditary chronic pancreatitis. In: Encyclopedia of Pathology, H. V. Krieken (ed.), Springer Nature Switzerland AG 2020.
- 13) Hackeng W, **Luchini C**, Brosens LAA. Glucagon cell hyperplasia and neoplasia. In: Encyclopedia of Pathology, H. V. Krieken (ed.), Springer Nature Switzerland AG 2020.
- 14) Mattiolo P, Lever V, Nottegar A, **Luchini C**, Brosens LAA. Haemochromatosis. In: Encyclopedia of Pathology, H. V. Krieken (ed.), Springer Nature Switzerland AG 2020.
- 15) Kryklyva V, **Luchini C**, Brosens LAA. Familial and Inherited Pancreatic Cancer. In: Encyclopedia of Pathology, H. V. Krieken (ed.), Springer Nature Switzerland AG 2020.
- 16) D'Onofrio M, Capelli P, De Robertis R, **Luchini C**, Tinazzi Martini P, Crosara S, Barbi E, Morana G. Mucinous neoplasms. In: Imaging and pathology of pancreatic neoplasms, editors D'Onofrio M, Capelli P, Pederzoli P. Springer 2015.
- 17) Capelli P, Tinazzi Martini P, D'Onofrio M, Morana G, De Robertis R, **Luchini C**, Canestrini S, Gobbo S, Pozzi Mucelli R. Serous neoplasms. In: Imaging and pathology of pancreatic neoplasms, editors D'Onofrio M, Capelli P, Pederzoli P. Springer 2015.
- 18) Morana G, D'Onofrio M, Tinazzi Martini P, De Robertis R, Crosara S, **Luchini C**, Manfredi R, Capelli P. IPMN. In: Imaging and pathology of pancreatic neoplasms, editors D'Onofrio M, Capelli P, Pederzoli P. Springer 2015.
- 19) Frulloni L, Amodio A, Vantini I, Dal Molin M, Inama M, D'Onofrio M, Marcolini L, **Luchini C**, Butturini G, Capelli P. Tumor-like lesions of the pancreas. In: Uncommon pancreatic neoplasm, editors Pederzoli P, Bassi C. Springer 2011.

Capitoli di libri (tiratura nazionale)

- 20) Scarpa A, Mattiolo P, **Luchini C**. Patologia Molecolare Terapeutica. In: Manuale di Anatomia Patologica Funzionale. Pelosi G, Sapino A, Maiorano E (ed.). Edizioni Minerva Medica, Torino, 2022
- 21) Scarpa A, Simbolo M, **Luchini C**. Il profilo molecolare. In: Il carcinoma del pancreas, editors: Pinto C, Tortora G, Il Pensiero Scientifico Editore, Roma, 2017.

PARTECIPAZIONE / PRESENTAZIONI ORALI A CONGRESSI E PUBBLICAZIONI IN FORMA DI ABSTRACT

Presentazioni orali a convegni e congressi di abstract accettati come comunicazione orale

1. B-RAF and ALK assesement in a subset of pulmonary enteric adenocarcinomas. Congresso Nazionale della Società Italiana di Anatomia Patologica e Citopatologia Diagnostica (SIAPEC-IAP), Roma, 26-30 Ottobre 2013.
2. NGS in molecular diagnosis. Workshop/college of pathology professors, Pisa, 8-10 maggio 2014.
3. Specific Expression Pattern of EMT Markers in Gestational Molar Disease. Congresso Nazionale della Società Italiana di Anatomia Patologica e Citopatologia Diagnostica (SIAPEC-IAP), Milano, 23-25 Settembre 2013
4. Extranodal extension of nodal metastasis in vulvar cancer and other solid malignancies: from histology to clinical practice. PCS 2nd Annual Gynaecological Oncology Symposium, Roma, 8-9 luglio 2017.
5. Extranodal extension of nodal metastasis amd prognosis in cancer: the surgical pathologist's point of view. 13th European Pathology Congress – Young Researchers Forum, Milano, 2-3 agosto 2017.
6. Molecular and clinical analysis of undifferentiated carcinoma of the pancreas with osteoclast-like giant cells. Congresso Nazionale della Società Italiana di Anatomia Patologica e Citopatologia Diagnostica (SIAPEC-IAP), Napoli, 12-14 Ottobre 2017.
7. Expression pattern and clinical implications of immunotherapy targets PD-1, PD-L1 and CD163 in undifferentiated carcinoma of the pancreas with osteoclast-like giant cells. International Conference on Pancreatic Cancer 2018, Baltimore, MD, USA, 26-29 Aprile 2018.
8. Comprehensive biological analysis of undifferentiated carcinoma of the pancreas with osteoclast-like giant cells. 3rd World Congress on Cancer Biology and Immunology, Milano, 11-12 Marzo 2019.
9. Integrative characterization of pancreatic intraductal tubulopapillary neoplasm (ITPN) and associated invasive adenocarcinoma. 18th ICGC Scientific Workshop, Verona, 14 giugno 2022.

Presentazioni orali a convegni, webinar e congressi nazionali come relatore su invito

10. Slide seminar di patologia digestiva: Next-generation histopathologic diagnosis. Congresso Nazionale della Società Italiana di Anatomia Patologica e Citopatologia Diagnostica (SIAPEC-IAP), Roma, 26-30 Ottobre 2013.
11. Approccio immunoistochimico ai chromatin remodelers: applicazioni diagnostiche e predittive. Congresso Nazionale della Società Italiana di Anatomia Patologica e Citopatologia Diagnostica (SIAPEC-IAP), Napoli, 12-14 Ottobre 2017.
12. Implicazioni del profilo genetico del tumore pancreatico. Convegno “ablazioni pancreatiche”, Verona, 10-11 Novembre 2017.
13. Diagnostica molecolare G.I.: nuove prospettive. Congresso “Master Class in Oncologia, Tumori G.I. – 6° edizione”, Firenze, 8-9 Marzo 2018.
14. Relatore al convegno “Neoplasie Neuroendocrine: Expert Opinion”, titolo: “Genetic landscape of PanNENs”, Brescia, 23 Marzo 2018.
15. Next-generation histopathologic diagnosis. “Vie di diffusione linfatica delle neoplasie dell'apparato digerente”, Brescia, 16 Maggio 2018.
16. Diagnosi Molecolare. “Proposta di PDTA per pazienti affetti da tumori del pancreas – Rete Oncologica Veneta”. Padova, 27 Settembre 2018.
17. Relatore al congresso: "2019: Oncologia di Precisione", tenutosi a Roma in data 24-25 maggio 2019, con relazione dal titolo: "Dall'istologia al profilo molecolare: approccio diagnostico integrato alle neoplasie".
18. Relatore al convegno "12° Confronto di Qualità in Immunoistochimica: test ad alto valore diagnostico-predittivo" tenutosi a Negrar in data 31 maggio / 1 giugno 2019, con relazione nella sessione "instabilità dei microsatelliti - carcinoma coloretale" dal titolo: "Il ruolo del Patologo".
19. Relatore al webinar organizzato dal Gruppo Italiano Patologi Apparato Digerente (GIPAD): "Integrazione tra morfologia e patologia molecolare nella caratterizzazione delle neoplasie".

- neuroendocrine GEP", con relazione dal titolo: "Novità classificative e molecolari delle neoplasie neuroendocrine del pancreas", tenutosi in modalità online / webinar in data 16 ottobre 2020.
20. Relatore al Webinar Maxi Gumm-2 young pathologists meet young oncologists, 18-19 febbraio 2021. "Carcinoma dello stomaco: classificazione WHO, nuovi orizzonti morfo-molecolari".
 21. Relatore al Corso Nazionale di Chirurgia Pancreatica, Verona, 18-20 ottobre 2021. "Il ruolo del patologo".
 22. Relatore al Corso Nazionale di Chirurgia Pancreatica, Verona, 18-20 ottobre 2021. "Le neoplasie cistiche: classificazione".
 23. Relatore al Congresso Annuale SIAPeC-IAP 2021. Patologia molecolare, NGS seminar: "Esempi diagnostici risolti con NGS – Tratto pancreatico-biliare". 23-27 Novembre 2021, Virtual Congress.
 24. Relatore al webinar "MSI e MMR come marcatori predittivi all'immunoterapia nel mCRC", titolo: "Le raccomandazioni ESMO sul test di instabilità microsatellitare e relazione tra MMR e gli altri biomarcatori implicati nella selezione del paziente da sottoporre ad immunoterapia", 24 febbraio 2022.
 25. Relatore al webinar "Anatomia patologica del tratto gastroenterico: dalla diagnosi istologica ai biomarcatori molecolari", 19 maggio 2022. "Adenocarcinoma duttale: diagnosi differenziale, istotipi rari e marcatori prognostico-predittivi".
 26. Relatore al webinar "Neoplasie Neuroendocrine: Expert Opinion", titolo: "Il microambiente immunitario nei tumori neuroendocrini del pancreas", 17 giugno 2022.
 27. Slide seminar: "presentazione di casi di colangiocarcinoma". Nuovi orizzonti diagnostici molecolari nel colangiocarcinoma. Webinar 18 luglio 2022.
 28. Relatore al Convegno VIII Incontro nazionale gruppo italiano di patologia molecolare e medicina predittiva, Firenze 12-14 settembre 2022. "Carcinomi del pancreas".
 29. Relatore al Corso Nazionale di Chirurgia Pancreatica, Verona, 24-26 ottobre 2022. "Il genoma dei tumori del pancreas".
 30. Relatore al Corso Nazionale di Chirurgia Pancreatica, Verona, 24-26 ottobre 2022. "Il ruolo del patologo".
 31. Relatore al Corso Nazionale di Chirurgia Pancreatica, Verona, 24-26 ottobre 2022. "Le neoplasie cistiche del pancreas".
 32. Relatore al convegno Strategie di screening e prevenzione dei tumori digestivi: il progetto europeo. Roma, 16 febbraio 2023. "Proteogenomica dei tumori del pancreas"
 33. Relatore al Webinar "Nuovi orizzonti istopatologici e molecolari in oncologia gastrointestinale", 10 maggio 2023. "Valutazione agnostica dello stato di MSI/MMR nel tratto gastrointestinale".
 34. Relatore al Corso "I tumori del pancreas: dalla diagnosi alla terapia", Pavia, 19 maggio 2023. "Tumori solidi NET, sottotipi istologici: rilevanza clinica".
 35. Relatore al Congresso Annuale di Anatomia Patologica SIAPeC-IAP, Napoli 19-21 ottobre 2023. "Algoritmo diagnostico nella valutazione delle piccole biopsie pancreatiche".
 36. Relatore al Convegno Pancreas ReUnion 2024, Forlì, 18-19 aprile 2024. "Molecular classification and tumour functional behaviour".
 37. Relatore al Convegno X Incontro nazionale gruppo italiano di patologia molecolare e medicina predittiva, Firenze 14-16 maggio 2024. "L'evoluzione dei biomarcatori per il colangiocarcinoma".
 38. Relatore al 6° Workshop dell'anatomia patologica 1 INT, La predittività clinica della surgical pathology, Milano, 14 giugno 2024. "I carcinomi delle vie biliari".
 39. Relatore al Congresso Annuale di Anatomia Patologica SIAPeC-IAP, Giardini Naxos – Messina, 7-9 Novembre 2024. "Genetica delle neoplasie neuroendocrine gastroenteropancreatiche: quale ruolo nella pratica clinica?".
 40. Relatore al Convegno "Right O-NTRack", Schiavon, 28 novembre 2024. "NTRK come bersaglio agnostico: aspetti biologici e diagnostici".
 41. Relatore al Convegno della Scuola Medica Ospedaliera, Verona, 12 dicembre 2024. "Il carcinoma del pancreas: la biologia molecolare".
 42. Relatore al convegno "Carcinoma gastrico e biomarcatori: eventi di formazione per i patologi", titolo: "Valutazione e refertazione dei nuovi target oltre Her2". 17 marzo 2025.
 43. Relatore al II Convegno del Gruppo Italiano di Patologia Endocrina (GIPE), Roma, 3-4 aprile 2025. "Profili molecolari dei tumori neuroendocrini pancreatici: valore diagnostico e prospettive cliniche".
 44. Relatore al II Convegno del Gruppo Italiano di Patologia Endocrina (GIPE), Roma, 3-4 aprile 2025. "Gli strumenti dell'AI pathology per la conta del Ki-67 nelle NEN: mito o realtà?"

45. Relatore al Congresso Arena 2025 Pancreas MM Multidisciplinare Multimodale Verona, 11-12 aprile 2025. “Pancreatite mass forming, paraduodenale ed autoimmune: aspetti cisto-istologici”.
46. Relatore al Congresso Arena 2025 Pancreas MM Multidisciplinare Multimodale Verona, 11-12 aprile 2025. “Adenocarcinoma duttale: caratteristiche cisto-istologiche e molecolari”.
47. Relatore al Congresso Arena 2025 Pancreas MM Multidisciplinare Multimodale Verona, 11-12 aprile 2025. “Neoplasie neuroendocrine: caratteristiche cisto-istologiche e molecolari”.
48. Relatore all’incontro “Aggiornamenti sui tumori epato-biliari”, Centro Malattie Epato-Biliari, AOUI Verona, Verona 15 aprile 2025. “Profilo mutazionale neoplasie epatiche: colangiocarcinomi”.
49. Relatore all’incontro “Aggiornamenti sui tumori epato-biliari”, Centro Malattie Epato-Biliari, AOUI Verona, Verona 15 aprile 2025. “Profilo mutazionale neoplasie epatiche: epatocarcinomi”.
50. Relatore allo Spring Meeting dell’Associazione Italiana per lo Studio del Pancreas (AISP), Rovereto 8-9 maggio 2025. “Standardizzazione del referto anatomo-patologico e profilazione molecolare”.
51. Relatore al 7° Workshop dell’anatomia patologica 1 INT, La predittività clinica della surgical pathology, Milano, 13 giugno 2025. “Adenocarcinoma del pancreas: diagnostica istologica e molecolare”.
52. Relatore al convegno “Trends in gastrointestinal pathology”, Padova 26 giugno 2025. “MMR/MSI: linee guida e prevalenza in ambito gastrointestinale”.
53. Relatore al convegno “Trends in gastrointestinal pathology”, Padova 26 giugno 2025. “La diagnostica molecolare in ambito gastrointestinale: dalle innovazioni dei progetti ICGC/TCGA alla pratica clinica”.

Presentazioni orali a convegni, webinar e congressi internazionali come relatore su invito

54. Relatore al 27th European Congress of Pathology, Belgrado, Serbia, 5-9 Settembre 2015. Titolo relazione: “Routine pathology molecular diagnostics: dealing with tumor heterogeneity”.
55. Relatore al 33rd European Congress of Pathology, virtual meeting, 29-31 agosto 2021. Titolo relazione: “Intraductal tubulopapillary neoplasms (ITPN) & intraductal oncocytic papillary neoplasms (IOPN)”.
56. Relatore al 34th European Congress of Pathology, Basel, Switzerland, 3-7 Settembre 2022. Titolo relazione: “Tumour mutational burden and MSI: too fancy?”.
57. Relatore al 112th USCAP Annual Meeting, New Orleans, USA, 11-16 marzo 2023. Titolo relazione: “Diagnostic pearls and pitfalls in the evaluation of small biopsies of the pancreas”.
58. Relatore al Vladimir Totovic Memorial Symposium, German Division of IAP and the Vladimir Totović Foundation, online webinar, 10 giugno 2023. Titolo relazione: “Molecular targets in pancreatic cancer”.
59. Relatore al 55th Annual Meeting of the European Pancreatic Club, Alpbach, 28 giugno-1 luglio 2023. Titolo relazione: “Pancreatic cancer and its variants: from histology and genomics to the clinic”.
60. Relatore al 35th European Congress of Pathology, Dublin, Ireland, 9-13 Settembre 2023. Titolo relazione: “Videomicroscopy course: FNB Pancreatic lesions”.
61. Relatore al 35th European Congress of Pathology, Dublin, Ireland, 9-13 Settembre 2023. Titolo relazione: “The microenvironment of IPMN”.
62. Relatore al LXV Annual Mexican Congress / 70th Anniversary of the Mexican College and Association of Pathologists, Jurica Queretaro, Messico, 1-4 maggio 2024. Titolo relazione: “Pearls and pitfalls of pancreatic biopsies”.
63. Relatore al XXXV Intranational Academy of Pathology (IAP) Congress, Cancun, Messico, 27-31 ottobre 2024. Titolo relazione: “Slide Seminar Liver/Pancreas Pathology: neoplastic”.
64. Relatore al 2025 Sol Goldman International Think Tank on pancreatic cancer, 22 aprile 2025, Johns Hopkins University, Baltimore, USA. Titolo relazione: “Different epithelia in the pancreas: behind the enemy lines”.
65. Relatore al 57th Annual Meeting of the European Pancreatic Club, Düsseldorf, 2-5 luglio 2025. Titolo relazione: “Precursor lesions and early PDAC: genetics”.

Poster a primo nome

66. **Luchini C**, Wood LD, Cheng L, Nottesgar A, Capelli P, Stubbs B, Pea A, Solmi M, Sergi G, Manzato E, Fassan M, Bagante F, Bollschweiler E, Giacomuzzi S, Bencivenga M, Kaneko T, de Manzoni G, Veronese N, Barbareschi M, Scarpa A. Extranodal extension of nodal metastases is a poor prognostic indicator in upper gastro-intestinal malignancies. XXXI European Congress of Pathology, Colonia, Germania, 25-29 Settembre 2016, Acts of the Congress, Virchows Arch (special issue). Presentato come poster.
67. **Luchini C**, Capelli P, Fassan M, Simbolo M, Mafficini A, Ruzzenente A, Guglielmi A, Corbo V, Lawlor RT, Scarpa A. Paraffin embedded tissues use for next generation histopathologic diagnosis. European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) Conference, Verona, 8-11 October 2013, Acts of the Congress. Presentato come poster.

Collaborazione ad abstract sottomessi/presentati oralmente o come poster da altri autori

68. Paolino G, Mombello A, Bernasconi R, Lawlor RT, Scarpa A, **Luchini C**. A case of widespread metastatic pancreatic ductal adenocarcinoma, signet ring cell variant. 32nd Congress of the European Society of Pathology and XXXIII International Congress of the International Academy of Pathology.; 6-8 dicembre 2020. Virtual only.
69. Bernasconi G, Fiadone G, Paolino G, Lawlor RT, Scarpa A, **Luchini C**. Epithelial-to-mesenchymal transition in undifferentiated carcinoma of the pancreas with osteoclast-like giant cells. 32nd Congress of the European Society of Pathology and XXXIII International Congress of the International Academy of Pathology.; 6-8 dicembre 2020. Virtual only.
70. Taskin OC, Reid MD, Culci PB, Balci S, Armutlu A, Demirtas D, Pehlivanoglu B, Saka B, Memis B, Bozkurtlar E, Leblebici CB, Birceanu Corobea A, Xue Y, Erkan M, Kapran Y, Sokmensuer C, Scarpa A, **Luchini C**, Basturk O, Adsay NV. Histopathologic Infiltration Pattern Predicts Metastasis and Progression Better than pT-Stage and Grade in Well-Differentiated Pancreatic Neuroendocrine Tumors: A Proposal for an Infiltration-Based Morphologic Grading System. United States & Canadian Academy of Pathology (USCAP) 110th Annual Meeting; 13-18 marzo, 2021. Virtual only.
71. La Rosa S, Simbolo M, **Luchini C**, Albarello L, Scoazec JY, Schiavo Lena M, Sessa F, Scarpa A. MiNENs Composed of Adenocarcinoma and Well Differentiated Neuroendocrine Tumor Have a Monoclonal Origin. United States & Canadian Academy of Pathology (USCAP) - United States & Canadian Academy of Pathology, 109th Annual Meeting, Los Angeles, 28 febbraio-5 marzo 2020.
72. Cataldo I, Baggio S, Zanconato G, **Luchini C**, Parisi A, Manfrin E. Placental chorangioma: report of a giant case and of a seven years 16 cases collection. Pathologica 2013.
73. Nottesgar A, Brunelli M, Cingarlini S, Oliosi C, Brunello E, Pedron S, Doglioni C, Montagna L, **Luchini C**, Martignoni G and Chilosi M. Morphological, immunohistochemical and cytogenetic characterization of lung adenocarcinomas with enteric differentiation. Pathologica 2012.
74. Pedica F, Cataldo I, Marcolini L, **Luchini C**, Gobbo S, Parisi A, Capelli P. Adenosquamous carcinoma of the pancreas: a series of 12 cases. Pathologica 2011.
75. Gobbo S, **Luchini C**, Regi P, Girelli R, Frigerio I, Tinazzi P, Capelli P. Intrapancreatic accessory spleen. J Pancreas 2011; 12(5):551-552.
76. Nottesgar A, **Luchini C**, Cingarlini S, Beccari S, Grego E, Gilioli E, Manfrin E, Bonetti F. Pathological complete response in a patient affected by multiple synchronous breast and lung primary malignancies: a case report and review of the literature. Pathologica 2015.
77. Nottesgar A, **Luchini C**, Manfrin E, Parisi A, Brunelli M, Bria E, Bonetti F. Inflammatory breast carcinoma: high fidelity of morphological and molecular profiles before and after neoadjuvant treatment. Pathologica 2015.
78. Giuliani S, Ciniselli C, Leonardi E, Decarli N, **Luchini C**, Ferro A, Verderio P, Barbareschi M. HER2 in infiltrating breast carcinomas: analysis on 2164 cases with survival analysis on 116 cases treated with trastuzumab. Pathologica 2014. Presentato come poster.
79. Cappellesso R, Mescoli C, Capelli P, **Luchini C**, Sivieri F, Sarcognato S, Rugge M, Guido M. Differential diagnosis between bile duct adenoma and intrahepatic cholangiocarcinoma: an immunohistochemical algorithm. Pathologica 2014. Presentato come poster.

80. Bria E, Fassan M, Pilotto S, De Manzoni G, Kispnergher S, Sperduti I, Peretti U, Simbolo M, Capelli P, Tomezzoli A, **Luchini C**, Mafficini A, Turri G, Tortora G, Scarpa A. Molecular portrait of resected gastric cancer (RGC) with next generation sequencing (NGS) according to a clinical biological risk model considering FHIT, APC and HER-2 overexpression. European Society for Medical Oncology Congress 2014, Madrid, 26-30 Settembre 2014. Acts of Congress. Presentato come poster.
81. Lora V, **Luchini C**, Sabbadini C, Girolomoni G, Colato C. Pseudobollous Kaposi's sarcoma: case report and review of the literature. SIDEMAST Congress, Roma, Novembre 2012, Acts of the Congress. Presentato come poster.
82. Manfrin E, Remo A, Parisi A, Marcolini L, **Luchini C**, Macario M, Bonetti F. Detection of human epidermal growth factor receptor 2 protein. Can cytology specimens take the place of tissue sections? Pathologica 2011. Presentato come poster.

Membro del Comitato Organizzativo di convegni, webinar e congressi

1. Membro del Comitato Organizzativo del congresso "3rd World Congress on Cancer Biology and Immunology", Milano, 11-12 Marzo 2019.
2. Membro del Comitato organizzativo per il Companion Meeting della Pancreatobiliary Pathology Society al Congresso Annuale USCAP, Boston, USA, 23 marzo 2025.
3. Membro del Comitato organizzativo per il Companion Meeting della Pancreatobiliary Pathology Society al Congresso Annuale USCAP, San Antonio, USA, 22 marzo 2026.

Moderatore, Chair, Co-Chair a convegni, webinar e congressi

1. Chair della prima giornata del congresso "3rd World Congress on Cancer Biology and Immunology", Milano, 11-12 Marzo 2019.
2. Co-chair nella sessione "Global Health and Outcomes", al PCS 2nd Annual Gynaecological Oncology Symposium, Roma, 8-9 luglio 2017.
3. Co-chair nella sessione "Genital Cancers", al PCS 2nd Annual Gynaecological Oncology Symposium, Roma, 8-9 luglio 2017.
4. Co-chair nella sessione "Other Approach of Gynaecological Cancers", al PCS 2nd Annual Gynaecological Oncology Symposium, Roma, 8-9 luglio 2017.
5. Moderatore al convegno "Implementazione digitale dei percorsi diagnostici in anatomia patologica", Bolzano, 22 aprile 2022.
6. Moderatore al 34th European Congress of Pathology, Basel, Switzerland, 3-7 Settembre 2022, alla sessione comunicazioni orali patologia pancreatico ed epatica.
7. Chair al 36th European Congress of Pathology, Firenze, 7-11 settembre 2024, alla poster session su patologia gastrointestinale, epatica e pancreatico.
8. Chair al 57th Annual Meeting of the European Pancreatic Club, Düsseldorf, 4 luglio 2025, alla poster session su patologia pancreatico neoplastica.
9. Chair al 57th Annual Meeting of the European Pancreatic Club, Düsseldorf, 5 luglio 2025, alla Keynote Lecture "From H&E to 3D: towards a new understanding of pancreatic diseases" del prof. Ralph H. Hruban.

PREMI E RICONOSCIMENTI

Youppie (Young Pancreatologist platform in Europe) Award, Alpbach, Austria, 29 Giugno 2023, che viene consegnato durante il meeting annuale dello European Pancreatic Club (premio miglior pancreatologo europeo under 45).

IJMS (International Journal of Molecular Sciences) 2020 Young Investigator Award, Section of Molecular Biology

Abstract selezionato tra i migliori 20 abstracts, Congresso Nazionale della Società Italiana di Anatomia Patologica e Citopatologia Diagnostica (SIAPEC-IAP), Milano, 23-25 Settembre 2013.

Copertina (Cover Expert) del giornale World Journal Gastrointestinal Oncology per due diversi volumi.

Coautore su invito in 2 capitoli nella WHO Classification of Tumours, 5th edition, Genetic Tumour Syndromes (In Press e online beta version) e in 4 capitoli nella WHO Classification of Tumours, 6th edition, Digestive System Tumours [In Press]

Autorizzo il trattamento dei miei dati personali presenti nel curriculum vitae ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 “Codice in materia di protezione dei dati personali” e dell’art. 13 del GDPR (Regolamento UE 2016/679).

Verona, 02/04/2025

CLAUDIO LUCHINI